

**“RETINAL FINDINGS IN DIABETIC CHRONIC KIDNEY DISEASE PATIENTS  
AND NON - DIABETIC CHRONIC KIDNEY DISEASE PATIENTS: A  
COMPARATIVE STUDY.”**

By

**DR. SANJEET RAJESH GANDHI.**

Dissertation submitted to the  
B.L.D.E. (DEEMED TO BE UNIVERSITY)  
VIJAYAPURA, KARNATAKA



In Partial fulfilment of requirements for the degree of

**MASTER OF SURGERY**

**In**

**OPHTHALMOLOGY**

Under the guidance of

**PROF. (DR.) RAGHAVENDRA. K. IJERI**

MBBS, MS, FVRS.

Professor, Department of  
Ophthalmology

**B.L.D.E. (DEEMED TO BE UNIVERSITY)**

**Shri B.M. Patil Medical College Hospital and Research Centre**

**Vijayapura, Karnataka – 586103**

**2024**



**B.L.D.E. (Deemed to be University)**  
**Shri B.M. Patil Medical College Hospital and Research Centre**  
**Vijayapura, Karnataka**

**Declaration by the candidate**

*I, **DR. SANJEET RAJESH GANDHI**, hereby declare that this dissertation/thesis entitled “**RETINAL FINDINGS IN DIABETIC CHRONIC KIDNEY DISEASE PATIENTS AND NON - DIABETIC CHRONIC KIDNEY DISEASE PATIENTS: A COMPARATIVE STUDY.**” is a bonafide and genuine research work carried out by me under the guidance of **Prof. (Dr.) RAGHAVENDRA. K. IJERI** MBBS, MS, FVRS Professor, Department of Ophthalmology, B.L.D.E (DU) 's Shri B.M Patil Medical College, Hospital and Research Centre, Vijayapura.*

**Date:** 30/04/2025

**Place:** Vijayapura

**DR. SANJEET RAJESH  
GANDHI.**

**Postgraduate**

Department of Ophthalmology  
B.L.D.E. (Deemed to be University)  
Shri B.M. Patil Medical College  
Hospital and Research Centre  
Vijayapura, Karnataka



**B.L.D.E. (Deemed to be University)**  
**Shri B.M. Patil Medical College Hospital and Research Centre**  
**Vijayapura, Karnataka**

**Certificate by the Guide**

*This is to certify that the dissertation entitled “**RETINAL FINDINGS IN DIABETIC CHRONIC KIDNEY DISEASE PATIENTS AND NON - DIABETIC CHRONIC KIDNEY DISEASE PATIENTS: A COMPARATIVE STUDY**” is a bonafide and genuine research work carried out by **DR. SANJEET RAJESH GANDHI**. under my overall supervision and guidance in partial fulfilment of the requirement for the degree of M.S. in Ophthalmology.*

**Date:** 30/04/2025

**Place:** Vijayapura

**Prof. (Dr.) RAGHAVENDRA. K.**  
**IJERI**

**MBBS, MS Ophthalmology, FVRS**

**Professor**

Department of Ophthalmology  
B.L.D.E. (Deemed to be University)  
Shri B.M. Patil Medical College  
Hospital and Research Centre  
Vijayapura, Karnataka



**Dr. SANDEEP PATIL (MD,DM  
Nephrology)**

Associate Professor, Department of  
medicine.

B.L.D.E. (Deemed to be University)  
Shri B.M. Patil Medical College  
Hospital and Research Centre  
Vijayapura, Karnataka



**B.L.D.E. (Deemed to be University)**  
**Shri B.M. Patil Medical College Hospital and Research Centre**  
**Vijayapura, Karnataka**

**Endorsement by the Head of Department**

*This is to certify that the dissertation entitled “**RETINAL FINDINGS IN DIABETIC CHRONIC KIDNEY DISEASE PATIENTS AND NON - DIABETIC CHRONIC KIDNEY DISEASE PATIENTS : A COMPARATIVE STUDY**” is a bonafide and genuine research work carried out by **DR. SANJEET RAJESH GANDHI**. under the guidance of **Prof. (Dr.) RAGHAVENDRA. K. IJERI** MBBS, MS, DOMS, PhD (Medical) Professor and Head, Department of Ophthalmology. B.L.D.E (DU) 's Shri B.M Patil Medical College, Hospital and Research Centre, Vijayapura.*

**Date:** 30/04/2025

**Place:** Vijayapura

*Rekha*

**Prof. (Dr.) Rekha R Mudhol**  
MBBS, MS, DOMS, PhD (Medical)

**Professor and Head**  
Department of Ophthalmology  
B.L.D.E. (Deemed to be University)  
Shri B.M. Patil Medical College  
Hospital and Research Centre  
Vijayapura, Karnataka



**B.L.D.E. (Deemed to be University)**  
**Shri B.M. Patil Medical College Hospital and Research Centre**  
**Vijayapura, Karnataka**

**Endorsement by the Principal / Head of the Institution**

*This is to certify that the dissertation entitled “**RETINAL FINDINGS IN DIABETIC CHRONIC KIDNEY DISEASE PATIENTS AND NON - DIABETIC CHRONIC KIDNEY DISEASE PATIENTS : A COMPARATIVE STUDY**” is a bonafide and genuine research work carried out by **DR. SANJEET RAJESH GANDHI**. under the guidance of **Prof. (Dr.) RAGHAVENDRA. K. IJERI** MBBS, MS, DOMS, PhD (Medical) Professor and Head, Department of Ophthalmology. B.L.D.E (DU) 's Shri B.M Patil Medical College, Hospital and Research Centre, Vijayapura*

**Date:** 30/04/2025

**Place:** Vijayapura

**Prof. (Dr.) Aravind V. Patil**

**MS (Surgery)**

**Principal**

B.L.D.E. (Deemed to be University)  
Shri B.M. Patil Medical College  
Hospital and Research Centre  
Vijayapura, Karnataka



**B.L.D.E. (Deemed to be University)**  
**Shri B.M. Patil Medical College Hospital and Research Centre**  
**Vijayapura, Karnataka**

**COPYRIGHT**  
**Declaration by the candidate**

*I hereby declare that the BLDE (Deemed to be University), Vijayapura, Karnataka shall have the rights to preserve, use and disseminate this dissertation/thesis titled “**RETINAL FINDINGS IN DIABETIC CHRONIC KIDNEY DISEASE PATIENTS AND NON - DIABETIC CHRONIC KIDNEY DISEASE PATIENTS : A COMPARATIVE STUDY** in print or electronic format for academic/research purpose..*

**Date:** 30/04/2025

**Place:** Vijayapura

**DR. SANJEET RAJESH  
GANDHI.**

**Postgraduate**

Department of Ophthalmology  
B.L.D.E. (Deemed to be University)  
Shri B.M. Patil Medical College  
Hospital and Research Centre  
Vijayapura, Karnataka

**© B.L.D.E (Deemed to be University), Vijayapura, Karnataka**

## ACKNOWLEDGEMENT

*With a humble heart, I would like to begin this acknowledgement with a prayer to the Almighty God, who has given us the strength, wisdom, and grace to embark on this scholarly journey.*

*I am profoundly grateful to my teacher, mentor and guide, **Prof. (Dr.) RAGHAVENDRA. K. IJERI**, whose unwavering inspiration, encouragement, and support have been instrumental throughout my post-graduation studies and the preparation of my dissertation. Her guidance has been invaluable, and I deeply appreciate her dedication to my academic and professional growth.*

*I am deeply indebted to my esteemed Professors, **Dr. Rekha R Mudhol, Dr. Sunil Biradar and Dr Vallabha K**, as well as my Professor, **Dr. Raghavendra K Ijeri**, whose guidance and encouragement have propelled me to new heights of professional achievement throughout my course. Their mentorship has been instrumental in shaping my academic journey, and I am forever grateful for their invaluable support and inspiration.*

*My heartfelt thanks and deep gratitude to my teachers, **Dr. Keerti Wali, Dr. Talluru Subash, Dr. Shweta Patil, Dr. Magna Mary and Dr. Suman D**. Without their inspiration, timely guidance, immense support, and motivation, I wouldn't have been able to complete this dissertation.*

*I am grateful to **Dr. Aravind V Patil**, Principal of BLDE (DU) 's Shri B. M Patil Medical College Hospital and Research Centre, Vijayapura, for permitting me to utilise the resources in the completion of my work. I am extremely thankful*

*to **Dr. Vijaya Sorganvi** for her guidance in statistical analysis. I thank my friends and colleagues specially **Dr. Vaishnavi Patil** and **Dr. Shilpa K.** for their constant support.*

*I express my heartfelt appreciation and gratitude to my beloved parents, **Mr. Rajesh C Gandhi** and **Dr. Mrs. Soniya R Gandhi**, and my beloved brother **Sanat Gandhi** for their support, invaluable advice, and endless encouragement. Their boundless love and sacrifices have been the cornerstone of my journey, and I am deeply indebted to them for instilling in me the values of perseverance and determination.*

*Finally, I acknowledge my heartfelt gratitude to all my patients; this study would be incomplete without their participation.*

**DR. SANJEET RAJESH  
GANDHI.**

**Postgraduate**

Department of Ophthalmology  
B.L.D.E. (Deemed to be University)  
Shri B.M. Patil Medical College  
Hospital and Research Centre  
Vijayapura, Karnataka

## LIST OF CONTENTS

| Sl. no | Particulars                                   | Page no. |
|--------|-----------------------------------------------|----------|
| 1.     | Abstract                                      | 1-2      |
| 2.     | Introduction                                  | 3-4      |
| 3.     | Review of literature                          | 5-46     |
| 4.     | Materials and methods                         | 47-54    |
| 5.     | Results                                       | 55-71    |
| 6.     | Discussion                                    | 72-77    |
| 7.     | Limitations of the study                      | 78       |
| 8.     | Summary                                       | 79       |
| 9.     | Conclusion                                    | 80       |
| 10.    | Appendix I: Consent form                      | 81       |
| 11.    | Appendix II: Case proforma                    | 82-89    |
| 12.    | Appendix III: Institutional ethical clearance | 90       |
| 13.    | Appendix IV: Colour plates                    | 91-95    |
| 14.    | Appendix V: Master chart                      | 96-103   |
| 15.    | Appendix VI: Plagiarism report                | 104      |
| 16.    | References                                    | 105-119  |

## LIST OF ABBREVIATIONS

| Abbreviation | Full Form                                    |
|--------------|----------------------------------------------|
| CKD          | Chronic Kidney Disease                       |
| D-CKD        | Diabetic Chronic Kidney Disease              |
| ND-CKD       | Non-Diabetic Chronic Kidney Disease          |
| DM           | Diabetes Mellitus                            |
| DR           | Diabetic Retinopathy                         |
| NPDR         | Non-Proliferative Diabetic Retinopathy       |
| PDR          | Proliferative Diabetic Retinopathy           |
| SD-OCT       | Spectral-Domain Optical Coherence Tomography |
| OCT          | Optical Coherence Tomography                 |
| CST          | Central Subfield Thickness                   |
| pRNFL        | Peripapillary Retinal Nerve Fiber Layer      |
| RAAS         | Renin-Angiotensin-Aldosterone System         |
| RPE          | Retinal Pigment Epithelium                   |
| eGFR         | Estimated Glomerular Filtration Rate         |

**LIST OF TABLES**

| <b>S.No.</b> | <b>Title</b>                                               | <b>Page No.</b> |
|--------------|------------------------------------------------------------|-----------------|
| 1.           | Demographic Profile of Study Participants                  | 55              |
| 2.           | Glycemic and Renal Function Parameters                     | 56              |
| 3.           | Optical Coherence Tomography (OCT) Findings                | 57              |
| 4.           | Fundus Findings                                            | 58              |
| 5.           | Dialysis Distribution                                      | 59              |
| 6.           | eGFR vs Retinal/OCT Findings Summary                       | 60              |
| 7.           | Dialysis Status vs Retinal/OCT Changes                     | 61              |
| 8.           | Distribution of Non-Diabetic Etiologies Among CKD Patients | 62              |

**LIST OF GRAPHS**

| <b>S.No.</b> | <b>Title</b>                                            | <b>Page No.</b> |
|--------------|---------------------------------------------------------|-----------------|
| 1.           | Age Distribution of Study Participants                  | 55              |
| 2.           | Glycemic and Renal Function Parameters                  | 56              |
| 3.           | OCT Findings – Retinal Thickness in Different Quadrants | 57              |
| 4.           | Fundus Findings Distribution                            | 58              |
| 5.           | Dialysis Status Distribution                            | 59              |
| 6.           | eGFR Categories vs Retinal/OCT Findings                 | 60              |
| 7A.          | Dialysis Status vs Retinal/OCT Changes                  | 61              |
| 8.           | Etiology Distribution in ND-CKD Group (Pie Chart)       | 62              |

## **LIST OF FIGURES**

| <b>S.No.</b> | <b>Title</b>                                                             | <b>Page No.</b> |
|--------------|--------------------------------------------------------------------------|-----------------|
| 1.           | OCT Image of pRNFL Thickness in Control and ND-CKD Groups                | 46              |
| 2.           | Composite Fundus Images in CKD Patients with Various Retinal Appearances | 47              |

## ABSTRACT

### Introduction:

Chronic kidney disease (CKD) is a progressive multisystemic disorder with significant microvascular complications. The retina, due to its embryological and physiological similarity to renal vasculature, reflects systemic vascular changes, particularly in diabetic chronic kidney disease (D-CKD). This study aimed to compare retinal structural and vascular alterations in patients with D-CKD and non-diabetic CKD (ND-CKD), utilizing spectral-domain optical coherence tomography (SD-OCT) and fundus examination to determine the extent of microangiopathy across groups and its correlation with renal parameters.

### Methods:

A cross-sectional comparative study was conducted on 76 CKD patients (38 D-CKD and 38 ND-CKD) at a tertiary care hospital in Karnataka, India. All subjects underwent detailed ophthalmological evaluation including best-corrected visual acuity, intraocular pressure measurement, slit-lamp biomicroscopy, fundus photography, and SD-OCT imaging. Retinal thickness parameters were analyzed across five quadrants. Renal function was assessed using serum creatinine and estimated glomerular filtration rate (eGFR) via the Cockcroft-Gault formula. Fundus findings were classified according to standard retinopathy grading systems. Statistical comparisons were made using t-tests, chi-square, and correlation analyses.

### Results:

D-CKD patients demonstrated significantly greater retinal thinning across all macular quadrants ( $p < 0.001$ ), with mean subfoveal thickness of  $220.11 \pm 39.67 \mu\text{m}$  (RE) versus  $265.50 \pm 28.34 \mu\text{m}$  in ND-CKD. Proliferative and non-proliferative diabetic retinopathy were exclusive to the D-CKD group, while hypertensive retinopathy was more common in ND-CKD. A strong inverse correlation was observed between eGFR and retinal thinning ( $r = -0.65$ ,  $p < 0.01$ ). Patients on dialysis exhibited more severe OCT and fundus abnormalities. Among ND-CKD etiologies, hypertensive nephropathy was most associated with retinal microvascular signs.

### Conclusion:

Retinal changes in CKD reflect systemic microvascular pathology, with diabetic CKD demonstrating more advanced alterations due to synergistic effects of hyperglycemia and uremia. SD-OCT provides a sensitive

modality for detecting early neuroretinal damage. Routine retinal imaging may aid in risk stratification, progression monitoring, and interdisciplinary care planning in CKD patients. This study underscores the value of ophthalmic surveillance in nephrology protocols.

## INTRODUCTION

**Chronic kidney disease (CKD)** is a **global public health challenge** with an estimated prevalence of **9.1%**, affecting approximately **700 million individuals worldwide**, and accounting for **1.2 million deaths annually** <sup>(1)</sup>. CKD represents the **11th leading cause of death globally** and is projected to become the **5th leading cause of mortality by 2040** <sup>(2)</sup>. The disease burden is not uniformly distributed, with **developing countries** like **India** carrying a disproportionate share of cases due to the increasing prevalence of **diabetes mellitus (DM)** and **hypertension**, which are the primary risk factors for CKD <sup>(3)</sup>. In India, the prevalence of CKD is estimated to be **17.2%**, with nearly **6% of the population** suffering from advanced stages of CKD <sup>(4)</sup>. Within the state of **Karnataka**, data indicate a rising burden of CKD, largely attributed to **poorly managed diabetes, hypertension, and chronic glomerulonephritis**, with estimated prevalence rates of **15-20%** among high-risk populations <sup>(5)</sup>.

The growing epidemic of **CKD in India** reflects a combination of **demographic transition, urbanization, and lifestyle-related factors**, with **diabetic kidney disease (DKD)** accounting for **40-50% of cases** <sup>(6)</sup>. As of 2021, diabetes and hypertension contribute to **nearly 60% of CKD cases** in urban populations and **50% in rural areas** <sup>(7)</sup>. Moreover, the prevalence of **end-stage renal disease (ESRD)**, the most advanced stage of CKD, has shown a sharp rise, with **220–250 new ESRD cases per million population annually**, placing a heavy burden on the healthcare infrastructure <sup>(8)</sup>.

The **retina**, being **highly vascularized**, serves as a **window to systemic vascular health**, making it an important tool for evaluating microvascular changes in CKD. Both the **retina and kidneys** share similar **microvascular structures** and are affected by **common pathophysiological mechanisms** such as **endothelial dysfunction, oxidative stress, and the renin-angiotensin-aldosterone system (RAAS)** <sup>(9)</sup>. Retinal microvascular changes, such as

**arteriolar narrowing, venular dilatation, microaneurysms, and hard exudates**, have been well-documented in CKD patients, particularly in those with **diabetes** <sup>(10)</sup>. These findings provide valuable insights into systemic vascular health and are non-invasive compared to conventional diagnostic tools.

**Diabetic chronic kidney disease (D-CKD)** is a major contributor to the **global burden of CKD**, accounting for nearly **40% of all CKD cases worldwide** <sup>(11)</sup>. In India, the prevalence of **diabetic nephropathy** is estimated at **30-40% among individuals with diabetes**, making it the leading cause of CKD <sup>(12)</sup>. Karnataka, reflecting national trends, reports a high prevalence of D-CKD, with nearly **35-45% of CKD cases** attributed to poorly controlled diabetes and associated complications <sup>(13)</sup>. A study conducted in Bengaluru found that **over 50% of CKD patients** had diabetes as the primary etiology, underscoring the importance of integrated diabetes and CKD management in the state <sup>(14)</sup>.

While **non-diabetic CKD (ND-CKD)** encompasses a wide range of etiologies such as **hypertensive nephropathy, glomerulonephritis, and polycystic kidney disease**, its contribution to the global CKD burden is also significant, particularly in rural and resource-limited settings. Worldwide, ND-CKD accounts for approximately **60% of CKD cases**, with hypertension being the leading cause in **developed nations**, while **chronic infections and toxin exposure** are major contributors in **developing countries** <sup>(15)</sup>. In India, ND-CKD is more prevalent in rural areas, where **hypertension, chronic glomerulonephritis, and undiagnosed infections** are common causes, contributing to nearly **50% of CKD cases in these regions** <sup>(16)</sup>. In Karnataka, a study conducted in rural populations revealed a prevalence of **15-20% for ND-CKD**, with a significant proportion of cases attributable to **hypertension and undiagnosed renal conditions** <sup>(17)</sup>.

The retina offers a unique platform for evaluating the systemic vascular effects of CKD. Retinal findings, including **macular thinning**, **choroidal changes**, and **peripapillary retinal nerve fiber layer (pRNFL) thinning**, correlate with CKD progression and provide valuable diagnostic and prognostic information <sup>(18)</sup>. Advanced imaging techniques such as **spectral-domain optical coherence tomography (SD-OCT)** and **optical coherence tomography angiography (OCTA)** have emerged as non-invasive tools to assess these changes. Studies have shown that retinal imaging can detect microvascular abnormalities even in early stages of CKD, offering an opportunity for **early intervention** <sup>(19)</sup>.

The rising burden of **CKD worldwide**, especially in **India** and **Karnataka**, underscores the need for innovative diagnostic and management strategies. By comparing **retinal findings** in diabetic and non-diabetic CKD patients, this study aims to unravel distinct and overlapping mechanisms underlying systemic microvascular dysfunction. Such findings could pave the way for **integrated care models** that leverage retinal imaging as a non-invasive biomarker for CKD, improving early detection and management in high-risk populations.

## **AIM AND OBJECTIVES**

### **Aim:**

To study the retinal findings of diabetic chronic kidney disease patients and that of non-diabetic chronic kidney disease patients.

### **Objectives:**

- 1] To compare the retinal findings in patients of diabetic chronic kidney disease with that of non-diabetic chronic kidney disease.
- 2] To study the retinal findings in various non-diabetic causes of chronic kidney disease.

## **REVIEW OF LITERATURE**

The **KDIGO 2024 definition of chronic kidney disease (CKD)** emphasizes the importance of sustained abnormalities in kidney structure or function that persist for over three months and have significant implications for overall health. This definition encompasses a broad range of markers, including a **glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m<sup>2</sup>** and **markers of kidney damage** such as **albuminuria**, structural abnormalities, or other indicators detected through imaging or laboratory tests. By incorporating both functional and structural criteria, this definition highlights CKD as a long-term, progressive condition that impacts systemic health, including **microvascular complications in the retina**, necessitating early detection, comprehensive evaluation, and ongoing management to mitigate complications and improve patient outcomes.

### ***1. Epidemiology of Chronic Kidney Disease (CKD)***

CKD is recognized as a major public health concern worldwide, with a prevalence of **9.1% globally** and an estimated **1.2 million deaths annually** <sup>(1)</sup>. The increasing prevalence of CKD is particularly evident in low- and middle-income countries like India, where the prevalence is **17.2%** <sup>(2)</sup>. Diabetic kidney disease (DKD) accounts for **40-50% of CKD cases**, making it the leading cause of CKD <sup>(3)</sup>. In India, urban studies indicate that diabetes and hypertension contribute to **60% of CKD cases**, while rural studies reveal that chronic infections and undiagnosed nephropathies contribute significantly to **non-diabetic CKD (ND-CKD)** <sup>(4)</sup>.

### ***2. Pathophysiology of Retinal and Renal Microvascular Changes***

The **retina** and the **kidneys** share a similar microvascular structure and pathophysiological mechanisms, which explains their systemic connection in conditions like **chronic kidney disease (CKD)**. Both organs rely on intact microvascular networks to maintain their function, and damage to these networks can lead to **retinopathy** in the eye and **nephropathy** in the kidney. The major mechanisms involved in this pathological process include **oxidative stress**, **chronic inflammation**, **endothelial dysfunction**, and **activation of the renin-angiotensin-aldosterone system (RAAS)**, all of which collectively contribute to the microvascular damage observed in CKD.

### ***1) Oxidative Stress***

- i) **Oxidative stress** is one of the key mechanisms driving microvascular damage in both the retina and kidneys. In CKD, excessive production of **reactive oxygen species (ROS)** overwhelms the body's antioxidant defenses, leading to **oxidative damage** in endothelial cells and microvascular tissues. This is particularly relevant in diabetic CKD (D-CKD), where chronic hyperglycemia exacerbates ROS production through pathways such as the **polyol pathway**, **protein kinase C activation**, and the formation of **advanced glycation end products (AGEs)**. In the retina, oxidative stress leads to endothelial injury, which contributes to **increased vascular permeability**, **ischemia**, and the development of characteristic retinal findings such as **micro-aneurysms** and **cotton wool spots**. In CKD, oxidative stress also accelerates renal tubular damage, leading to fibrosis and a decline in glomerular filtration rate <sup>(1, 2)</sup>. Studies have shown that markers of oxidative stress, such as **malondialdehyde**, are elevated in both CKD and diabetic retinopathy patients, highlighting the shared mechanism <sup>(3)</sup>.

## 2) *Chronic Inflammation*

- i) **Chronic inflammation** is a hallmark of both CKD and retinal microvascular damage. In CKD, a pro-inflammatory state is induced due to the retention of **uremic toxins**, activation of immune pathways, and persistent low-grade infection. Pro-inflammatory cytokines such as **interleukin-6 (IL-6)**, **tumor necrosis factor-alpha (TNF- $\alpha$ )**, and **C-reactive protein (CRP)** are elevated in CKD patients, promoting endothelial damage and vascular remodeling. In the retina, inflammation leads to the release of **vascular endothelial growth factor (VEGF)**, which exacerbates vascular permeability and neovascularization. These processes result in retinal findings such as **macular edema** and **neovascularization**, particularly in diabetic retinopathy <sup>(4)</sup>. In non-diabetic CKD (ND-CKD), inflammation also drives microvascular changes, though without the direct effects of hyperglycemia, making the damage subtler but still significant.

## 3) *Endothelial Dysfunction*

- i) **Endothelial dysfunction** is a critical mechanism linking CKD and retinal microvascular damage. The endothelium regulates vascular tone, permeability, and blood flow. In CKD, **uremic toxins** such as **indoxyl sulfate** and **p-cresyl sulfate** impair endothelial function by reducing the availability of **nitric oxide (NO)**, a key vasodilator. This leads to **vasoconstriction**, **ischemia**, and increased vascular stiffness. Endothelial dysfunction is further aggravated in D-CKD by hyperglycemia and AGEs, resulting in capillary leakage and **vascular rarefaction** in both the retina and kidneys <sup>(5)</sup>. In the retina, these changes manifest as **cotton wool spots**, **venular dilatation**, and **hard exudates**. A study involving CKD patients demonstrated a strong association between reduced NO

bioavailability and the presence of retinal microvascular changes, emphasizing the systemic nature of endothelial dysfunction <sup>(6)</sup>.

#### 4) **Activation of the Renin-Angiotensin-Aldosterone System (RAAS)**

- i) The **renin-angiotensin-aldosterone system (RAAS)** plays a pivotal role in regulating blood pressure and fluid balance, but its over-activation in CKD contributes to widespread microvascular damage. Elevated levels of **angiotensin II** promote **vasoconstriction**, **endothelial injury**, and **fibrosis**. In the retina, RAAS activation is associated with **arteriolar narrowing**, **venular dilatation**, and **increased VEGF expression**, leading to pathological changes such as **neovascularization** in advanced stages of retinopathy. In CKD, the same mechanisms contribute to glomerular hypertension, proteinuria, and progressive kidney damage <sup>(7)</sup>. Clinical studies have shown that RAAS inhibitors, such as **angiotensin-converting enzyme (ACE) inhibitors** and **angiotensin receptor blockers (ARBs)**, can reduce the progression of both retinopathy and nephropathy by mitigating oxidative stress, inflammation, and VEGF overexpression <sup>(8)</sup>.

#### 5) ***Retinal Microvascular Changes in CKD***

The pathophysiological processes outlined above culminate in specific retinal microvascular changes that mirror the systemic vascular damage seen in CKD. These include:

**Arteriolar narrowing:** Due to chronic vasoconstriction and vascular remodeling, resulting in reduced oxygen delivery to retinal tissues.

**Venular dilatation:** Reflecting increased venous pressure and endothelial dysfunction.

**Microaneurysms:** Caused by weakened vascular walls and increased permeability.

**Cotton wool spots:** Indicative of retinal ischemia and microvascular occlusion.

**Macular edema and hard exudates:** Reflecting leakage of plasma proteins and lipids due to vascular permeability <sup>(9)</sup>.

A large-scale study of **7,228 participants** without diabetes found that retinopathy signs, such as microaneurysms and venular dilatation, were present in **25-30% of CKD patients**, underscoring the systemic vascular involvement in CKD <sup>(10)</sup>. These findings were more severe in D-CKD patients due to the combined effects of hyperglycemia and CKD-related vascular dysfunction.

### ***3. Retinal Findings in Diabetic Chronic Kidney Disease (D-CKD)***

**Diabetic chronic kidney disease (D-CKD)** is associated with distinct retinal abnormalities due to the combined effects of **hyperglycemia, hypertension, and microvascular complications**. The interplay between systemic vascular dysfunction and localized retinal damage leads to several characteristic retinal findings in D-CKD.




Fig 1. OCT image of pRNFL thickness measurement for controls and NDCKD group. (A) Control group (B) NDCKD group. Abbreviation:

Figure 1. OCT image of pRNFL thickness measurement for controls and NDCKD group. (A) Control group (B) NDCKD group. Abbreviation: pRNFL = peripapillary retinal nerve fiber layer; NDCKD = non-diabetic chronic kidney disease

1. Diabetic Retinopathy (DR):

Diabetic retinopathy is present in up to **95% of patients with D-CKD**. It represents a spectrum of retinal changes ranging from **non-proliferative diabetic retinopathy (NPDR)**, characterized by microaneurysms, intraretinal hemorrhages, and hard exudates, to **proliferative diabetic retinopathy (PDR)** with neovascularization and vitreous hemorrhage<sup>(1)</sup>. The development of DR is driven by hyperglycemia-induced oxidative stress, endothelial dysfunction, and

the upregulation of vascular endothelial growth factor (VEGF) <sup>(2)</sup>. Studies have shown that the **severity of DR correlates with CKD progression**, suggesting a shared pathophysiological pathway between the two conditions <sup>(3)</sup>.

## 2. **Choroidal Thinning:**

Structural changes in the **choroid**, as assessed by **spectral-domain optical coherence tomography (SD-OCT)**, reveal significant thinning in D-CKD patients. The choroid is essential for retinal health as it supplies oxygen and nutrients to the outer retina. Hyperglycemia-induced ischemia and VEGF overexpression lead to choroidal thinning, which is more pronounced in advanced stages of diabetic nephropathy <sup>(4)</sup>. A study by Da Silva et al. demonstrated that **choroidal thinning** was significantly associated with **reduced estimated glomerular filtration rate (eGFR)** in diabetic CKD patients <sup>(5)</sup>.


## 3. **Macular Edema:**

**Macular edema**, a hallmark of advanced diabetic retinopathy, is commonly observed in D-CKD patients. It results from **increased vascular permeability** caused by endothelial dysfunction and VEGF overexpression <sup>(6)</sup>. Macular edema contributes significantly to **visual impairment** and is exacerbated by poorly controlled diabetes and CKD <sup>(7)</sup>. Studies have also shown that macular edema is more prevalent in patients with **proteinuria**, a marker of advanced diabetic nephropathy <sup>(8)</sup>.

## 4. **Peripapillary Retinal Nerve Fiber Layer (pRNFL) Thinning:**

The **pRNFL**, which consists of the axons of retinal ganglion cells, shows significant thinning in D-CKD patients. This is attributed to microvascular ischemia, oxidative stress, and neurodegeneration <sup>(9)</sup>. SD-OCT studies reveal that thinning is more prominent in the **superior and inferior quadrants** of the pRNFL and correlates with CKD progression <sup>(10)</sup>.

A **population-based study of 28,344 diabetic patients** highlighted a strong correlation between **CKD progression and DR severity**, emphasizing the systemic vascular implications of diabetic nephropathy on the retina <sup>(11)</sup>.



*Figure 2. Retinal appearances in patients with chronic kidney disease stages 3 to 5: (a) thrombosed vessel and retinal atrophy secondary to severe hypertension in focal segmental glomerulosclerosis, (b) multiple hemorrhages from retinal vein thrombosis, (c) undiagnosed diabetic retinopathy, (d) fibrous change in diabetic retinopathy with hemorrhage and exudates, (e) central drusen in macular degeneration, (f) severe geographic atrophy in macular degeneration, (g) macular drusen in a young patient with dense deposit disease, and (h) retinal*

*atrophy in patient with focal segmental glomerulosclerosis and Myopathy, Encephalopathy, Lactic Acidosis, Stroke-like episodes syndrome.*

#### **4. Retinal Findings in Non-Diabetic Chronic Kidney Disease (ND-CKD)**

Although **non-diabetic CKD (ND-CKD)** is less frequently associated with retinal changes compared to D-CKD, significant findings have been reported. These changes are primarily driven by **uremic toxins, chronic inflammation, and endothelial dysfunction.**

##### **1. Macular Thinning:**

SD-OCT studies reveal significant **macular thinning** in ND-CKD patients compared to healthy controls. This thinning is attributed to the accumulation of uremic toxins and microvascular ischemia, which impair retinal health (12). Unlike diabetic CKD, macular thinning in ND-CKD is not associated with VEGF overexpression or exudative changes, making it subtler in presentation <sup>(13)</sup>.

##### **2. pRNFL Thinning:**

Similar to D-CKD, ND-CKD patients also exhibit **thinning of the pRNFL**, particularly in the **temporal and inferior quadrants**. This thinning is linked to systemic endothelial dysfunction and neurodegeneration caused by the retention of uremic toxins <sup>(14)</sup>. A study by Chow et al. demonstrated that pRNFL thinning in ND-CKD was detectable even in early stages of CKD, underscoring its diagnostic value <sup>(15)</sup>.

##### **3. Microvascular Abnormalities:**

Retinal microvascular abnormalities, including **capillary rarefaction** and **arteriolar narrowing**, have been observed in ND-CKD patients. These changes are driven by chronic inflammation and oxidative stress, which impair retinal perfusion <sup>(16)</sup>. Unlike D-CKD, these changes are less severe and do not typically progress to neovascularization or exudative retinopathy.

In a study involving **132 ND-CKD patients**, retinal abnormalities were detected even in early stages of CKD, highlighting the systemic nature of the disease and the potential role of retinal imaging in early diagnosis <sup>(17)</sup>.

### ***5. Comparative Retinal Findings: D-CKD vs. ND-CKD***

Chronic kidney disease (CKD) presents with systemic microvascular complications that manifest in the retina, providing a unique opportunity to differentiate and understand the distinct effects of **diabetic chronic kidney disease (D-CKD)** and **non-diabetic chronic kidney disease (ND-CKD)**. Retinal findings in both groups are shaped by shared pathophysiological mechanisms, including microvascular ischemia, oxidative stress, and inflammation, but are influenced by the additional impact of **hyperglycemia** in D-CKD. The following section elaborates on the differences and overlaps between these two groups, supported by recent scientific evidence.

### ***1. Diabetic Chronic Kidney Disease (D-CKD)***

**D-CKD** is characterized by more severe and progressive retinal changes due to the combined effects of **hyperglycemia** and **CKD-associated microvascular dysfunction**. Key retinal findings in D-CKD include:

#### **1. Proliferative Diabetic Retinopathy (PDR):**

The hallmark feature of D-CKD is **proliferative diabetic retinopathy**, driven by **vascular endothelial growth factor (VEGF)** overexpression and chronic ischemia. Neovascularization, vitreous hemorrhage, and tractional retinal detachment are more prevalent in D-CKD due to the synergistic effects of CKD progression and poorly controlled diabetes <sup>(1)</sup>.

#### **2. Macular Edema:**

**Macular edema**, a major cause of visual impairment in D-CKD, occurs due to increased vascular permeability, which leads to the accumulation of fluid in the macula. Studies have shown that macular edema is significantly more common in D-CKD patients with advanced proteinuria and poor glycemic control, further emphasizing the role of systemic factors <sup>(2)</sup>.

#### **3. Choroidal Thinning:**

The **choroid**, a vascular layer critical for retinal oxygenation, shows significant thinning in D-CKD. This is attributed to chronic ischemia and VEGF-mediated changes, with greater thinning observed in patients with higher levels of albuminuria and reduced estimated glomerular filtration rate (eGFR) <sup>(3)</sup>.

Choroidal thinning has been strongly correlated with disease severity in D-CKD

(4).

#### 4. **Central Subfield Thickness (CST):**

The **central subfield thickness (CST)** is often increased in D-CKD due to macular edema but shows signs of thinning in advanced stages as a result of retinal atrophy. Studies using spectral-domain optical coherence tomography (SD-OCT) have highlighted significant changes in CST in patients with D-CKD, providing insights into disease progression (5).

## 2. ***Non-Diabetic Chronic Kidney Disease (ND-CKD)***

In contrast to D-CKD, **ND-CKD** is characterized by more subtle retinal changes. These changes are primarily driven by **uremic toxins**, **endothelial dysfunction**, and **chronic inflammation**, without the added effects of hyperglycemia.

### 1. **Macular Thinning:**

**Macular thinning** is a prominent feature in ND-CKD, as shown by SD-OCT studies. This thinning is attributed to microvascular ischemia and neuronal loss, which are aggravated by elevated levels of uremic toxins such as indoxyl sulfate and p-cresyl sulfate (6). Unlike D-CKD, macular thinning in ND-CKD is not accompanied by exudative changes or edema.

## 2. **pRNFL Thinning:**

**Peripapillary retinal nerve fiber layer (pRNFL)** thinning is a significant finding in ND-CKD patients. The thinning is particularly evident in the temporal and inferior quadrants of the retina and correlates with disease severity and systemic vascular dysfunction (7). This suggests a strong link between kidney function and retinal neuronal health in ND-CKD.

## 3. **Microvascular Abnormalities:**

Retinal microvascular abnormalities, including arteriolar narrowing, venular dilation, and capillary rarefaction, are common in ND-CKD. These changes reflect the systemic vascular effects of uremic toxins and chronic inflammation. However, they are less severe compared to the proliferative and exudative features seen in D-CKD (8).

*Comparative Analysis of Retinal Findings*

While both D-CKD and ND-CKD exhibit retinal microvascular damage, distinct differences in the severity and nature of these changes exist

| Feature                     | D-CKD                                                                 | ND-CKD                                                                        |
|-----------------------------|-----------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Proliferative changes       | Proliferative diabetic retinopathy with neovascularization is common. | Rarely observed.                                                              |
| Macular changes             | Macular edema and exudates are prominent.                             | Macular thinning without exudates is common.                                  |
| Choroidal thinning          | Significant and associated with advanced CKD and diabetes.            | Mild to moderate thinning observed.                                           |
| pRNFL thinning              | Severe thinning due to ischemia and hyperglycemia-induced damage.     | Moderate thinning, particularly in the temporal and inferior quadrants.       |
| Microvascular abnormalities | Severe vascular leakage, microaneurysms, and hemorrhages.             | Subtle vascular changes, including arteriolar narrowing and venular dilation. |

**6. Role of Retinal Imaging in CKD**

Advances in imaging technology have revolutionized the ability to detect and monitor retinal changes in CKD patients. Retinal imaging has emerged as a critical tool in understanding systemic vascular health in CKD, offering non-invasive insights into disease severity and progression.

**1. Spectral-Domain Optical Coherence Tomography (SD-OCT):**

SD-OCT provides high-resolution cross-sectional images of the retinal and choroidal layers. It is particularly useful in detecting:

- **Macular thinning** in ND-CKD.
- **Macular edema** and **choroidal thinning** in D-CKD (10).
- Studies have shown that SD-OCT can detect subtle changes in the retina even in the early stages of CKD, making it a valuable tool for early diagnosis.

## 2. **Optical Coherence Tomography Angiography (OCTA):**

OCTA is a non-invasive imaging technique that visualizes the retinal microvasculature. It is especially valuable for identifying:

- **Capillary non-perfusion** in ND-CKD.
  - **Neovascularization** and **microaneurysms** in D-CKD (11).
- OCTA provides quantitative data on retinal blood flow, offering insights into systemic vascular health.

## 3. **Fundus Photography:**

Fundus photography is a simple, cost-effective imaging modality for detecting:

- **Microaneurysms, hard exudates, and hemorrhages** in D-CKD.
  - **Subtle vascular changes**, such as arteriolar narrowing, in ND-CKD (12).
- Although it lacks the depth of SD-OCT and OCTA, it remains a valuable screening tool, particularly in resource-limited settings.

## 4. **Role of Imaging as a Biomarker:**

Retinal imaging is increasingly recognized as a **non-invasive biomarker** for CKD severity and progression. The correlation between retinal findings and systemic markers

of CKD, such as **eGFR** and **albuminuria**, underscores its clinical utility. Imaging techniques like SD-OCT and OCTA are particularly useful for monitoring disease progression and evaluating the effectiveness of therapeutic interventions (13).

## 7. Systemic Implications of Retinal Findings in CKD

Retinal findings in chronic kidney disease (CKD) patients are not limited to ocular health but serve as valuable indicators of systemic vascular health. The retina's richly vascularized structure mirrors systemic microvascular integrity, making it a key site for detecting systemic complications of CKD. One of the most significant systemic implications of retinal abnormalities in CKD is their strong correlation with cardiovascular risk. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in CKD patients, driven by shared mechanisms such as chronic inflammation, oxidative stress, and endothelial dysfunction. Retinal changes, including arteriolar narrowing, venular dilation, and microaneurysms, are associated with an increased risk of adverse cardiovascular outcomes such as myocardial infarction and stroke. Studies have demonstrated that the severity of retinopathy in CKD patients independently predicts cardiovascular events, underscoring its potential role as a non-invasive biomarker for cardiovascular risk stratification.

In diabetic CKD (D-CKD), retinal findings such as diabetic retinopathy (DR) have a predictive value for CKD progression. The shared pathophysiology of hyperglycemia-induced vascular damage in both the retina and kidneys results in similar patterns of microvascular injury. Patients with proliferative diabetic retinopathy (PDR) often experience a more rapid decline in glomerular filtration rate (GFR) and are at higher risk of developing end-stage renal disease

(ESRD). A large cohort study reported that moderate-to-severe DR was associated with a two-fold higher risk of CKD progression, highlighting the predictive value of retinal findings in managing D-CKD patients. Such findings emphasize the interconnected nature of retinal and renal microvascular health and the importance of early detection and management of DR to mitigate CKD progression.

In non-diabetic CKD (ND-CKD), retinal changes such as macular thinning, peripapillary retinal nerve fiber layer (pRNFL) thinning, and microvascular abnormalities reflect systemic endothelial dysfunction and inflammation. These changes are primarily driven by uremic toxins and chronic inflammation rather than hyperglycemia. Unlike D-CKD, retinal abnormalities in ND-CKD are more subtle, often limited to ischemic and degenerative changes without exudative or proliferative features. However, they remain significant as early indicators of systemic vascular dysfunction. Retinal findings in ND-CKD have been shown to correlate with elevated levels of inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), further highlighting their role as indicators of systemic inflammation and vascular injury. These insights underscore the potential of retinal imaging as a diagnostic and prognostic tool for identifying at-risk individuals in ND-CKD populations.

## **8. Gaps in Literature and Future Directions**

Despite substantial advancements in understanding the relationship between retinal changes and CKD, significant gaps remain, particularly in the context of non-diabetic CKD. Most existing studies focus on diabetic CKD, with limited research dedicated to exploring retinal findings in ND-CKD. This imbalance

highlights the need for further investigation into the unique retinal manifestations and systemic implications of ND-CKD. One major limitation is the lack of longitudinal studies tracking the progression of retinal changes alongside CKD progression. Cross-sectional studies provide valuable snapshots but fail to capture the dynamic relationship between systemic microvascular health and retinal changes over time. Longitudinal studies could provide deeper insights into how retinal findings evolve with CKD severity and whether targeted interventions, such as RAAS inhibitors or antioxidants, can mitigate these changes.

Another gap in the literature is the scarcity of population-based studies in developing regions, such as India, where the burden of CKD is disproportionately high. Risk factors such as poorly managed diabetes, hypertension, and chronic infections contribute significantly to the CKD burden in these regions. However, data on retinal findings in CKD patients from these populations remain scarce. Conducting large-scale, population-based studies in areas like Karnataka could help identify local risk factors and trends, offering region-specific insights into the interplay between systemic and retinal microvascular health. These studies would also provide valuable data to guide public health policies and screening protocols tailored to resource-limited settings.

Finally, there is a critical need to integrate retinal imaging into routine CKD screening protocols. While the systemic implications of retinal findings are well-established, retinal imaging is not yet widely adopted as a standard tool for CKD management. Barriers include limited access to advanced imaging

technologies such as spectral-domain optical coherence tomography (SD-OCT) and optical coherence tomography angiography (OCTA), especially in resource-constrained settings. Addressing these barriers requires the development of cost-effective imaging strategies, such as using fundus photography as a primary screening tool, and training healthcare providers to interpret retinal findings in CKD patients. Integrating retinal imaging into multidisciplinary care models, where ophthalmologists and nephrologists collaborate, could significantly enhance early detection and management of CKD and its systemic complications.

In conclusion, retinal findings in CKD patients offer a unique window into systemic vascular health, with significant implications for predicting cardiovascular risk, assessing CKD progression, and understanding microvascular dysfunction. Addressing the gaps in the literature, particularly through longitudinal studies, population-based research in developing regions, and the integration of retinal imaging into routine care, could pave the way for improved diagnostic and therapeutic strategies. By leveraging the insights gained from retinal imaging, healthcare providers can adopt a more comprehensive approach to CKD management, ultimately improving patient outcomes.

## **MATERIALS AND METHODS**

### ***1. Source of Data***

The study will be conducted at the **Department of Medicine and Nephrology** and the **Department of Ophthalmology** at **B.L.D.E. (Deemed to be University), Shri B.M. Patil Medical College, Hospital and Research Centre, Vijayapura**. Patients diagnosed with diabetic chronic kidney disease (D-CKD) and non-diabetic chronic kidney disease (ND-CKD) presenting to the outpatient (OPD) and inpatient (IPD) departments will be recruited for the study.

### ***2. Study Design***

This research adopts a **comparative cross-sectional study design**, focusing on identifying and analyzing differences in retinal findings between D-CKD and ND-CKD patients.

### ***3. Study Period***

The study will be conducted over a period of **one and a half years**, allowing sufficient time to recruit participants, perform detailed evaluations, and analyze the findings.

### ***4. Sample Size***

The anticipated **mean  $\pm$  standard deviation (SD)** of central subfield macular thickness (CSMT) is **278.95  $\pm$  45.02  $\mu\text{m}$**  for diabetic CKD patients and **231.89  $\pm$  26.72  $\mu\text{m}$**  for non-diabetic CKD patients. Based on this data:

- A minimum of **38 patients per group** (total **76 participants**) is required to achieve a **power of 99%** and a **level of significance of 5%** (two-sided).
- Sample size was calculated using the formula:

$$N = [(Z_{\alpha} + Z_{\beta}) \times S / d]^2$$

Where:

- **Z<sub>α</sub>**: Z-value for the level of significance (e.g., 1.96 for 95% confidence)
- **Z<sub>β</sub>**: Z-value for the power of the study (e.g., 0.84 for 80% power)
- **S**: Common standard deviation
- **d**: Clinically significant difference between two parameters

### ***5. Inclusion Criteria***

- Patients with **diabetic chronic kidney disease** attending the medicine/nephrology OPD/IPD.
- Patients with **non-diabetic chronic kidney disease** attending the medicine/nephrology OPD/IPD.
- Patients with existing CKD presenting to the ophthalmology OPD/IPD.

### ***6. Exclusion Criteria***

- Patients with **high myopia** or other developmental anomalies associated with increased axial length.
- Conditions causing **hazy media** such as corneal opacities, cataract, and vitreous hemorrhage that interfere with retinal readings.
- Patients with **retinal or choroidal detachment**.
- Patients who have previously received treatment for retinopathy.
- **Bedridden patients** unable to undergo ophthalmological examination.

## ***7. Patient Selection and Consent***

Participants will be selected according to the inclusion and exclusion criteria. Informed consent will be obtained after explaining the study's purpose, procedures, and potential risks. Confidentiality will be maintained throughout the study.

## ***8. Methods of Data Collection***

### **Clinical Evaluation**

A detailed history will be taken, including demographic details, occupational history, and medical, surgical, and ocular history. General and systemic examinations will be performed to assess the overall health and confirm eligibility.

### **Ophthalmologic Evaluation**

The following tests will be performed to evaluate retinal status:

1. **Visual Acuity Testing:** Using the logMAR chart.
2. **Fundoscopy:** Conducted with a slit lamp and a 90D lens for detailed retinal examination and indirect ophthalmoscopy for peripheral retinal evaluation.
3. **Fundus Photography:** Documenting retinal status post-pupillary dilation.
4. **Spectral-Domain Optical Coherence Tomography (SD-OCT):**
  - Performed using the ZEISS CIRRUS 500 HD-OCT system without pupillary dilation.
  - Enhanced Depth Imaging Optical Coherence Tomography (EDI-OCT) will be used for macular and choroidal thickness assessment.

- Retinal measurements will include **central subfield thickness (CST)** and **quadrant-specific thickness** (subfoveal, nasal, temporal, superior, and inferior regions).

## Nephrological Evaluation

1. **Renal Function Testing:** Estimation of glomerular filtration rate (eGFR) using serum creatinine levels

Estimation of glomerular filtration rate (eGFR) was done using serum creatinine levels, calculated via the Cockcroft-Gault formula, which incorporates age, weight, gender, and serum creatinine to approximate renal clearance, offering a reliable assessment in clinical nephrology practice.<sup>21</sup>

The **Cockcroft-Gault formula** is expressed as:

| Cockcroft-Gault Formula for Estimating Creatinine Clearance |                                                                                                                                                    |
|-------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| CrCl (mL/min)                                               | $= \frac{(140 - \text{age}) \times \text{Lean Body Weight (kg)}}{\text{Serum Creatinine (mg/dL)} \times 72} \quad (\times 0.85 \text{ if female})$ |

- **Age** is in years
- **Weight** is in kilograms
- **Serum Creatinine** is in mg/dL
- For women, the result is multiplied by **0.85** to adjust for lower average muscle mass

This formula assumes a steady-state creatinine level and is most accurate in adults with stable renal function. Despite the availability of newer methods such as CKD-EPI and MDRD,

Cockcroft-Gault remains widely utilized for **drug dose adjustments**, particularly in elderly and hospitalized patients.

#### Serum Creatinine and eGFR – Dual Renal Indices

Both **serum creatinine** and **eGFR** were measured in all participants to provide a comprehensive view of renal function. Serum creatinine, a byproduct of muscle metabolism, rises as glomerular function declines and is influenced by muscle mass and hydration status. In contrast, eGFR provides a standardized measure, adjusting for age, sex, and body size, offering a stage-based classification of CKD severity. The integration of these two indices enhances diagnostic precision, particularly in the early stages of renal impairment and in populations with high prevalence of malnutrition and sarcopenia.

#### Diabetic Status Evaluation

1. **Fasting Blood Sugar (FBS) and Postprandial Blood Sugar (PPBS):** To assess glycemic control.
2. **HbA1c Levels:** To determine long-term blood glucose control.

#### 9. Data Analysis

- Data will be recorded and entered into **Microsoft Excel**, and statistical analysis will be performed using **SPSS Version 20**.
- Results will be expressed as **Mean ± SD**, counts, percentages, and visualized using graphs and diagrams.
- Statistical tests will include:
  - **Independent t-test** for normally distributed continuous variables.
  - **Mann-Whitney U test** for non-normally distributed variables.

- **Chi-square test** for categorical variables.
- A **p-value < 0.05** will be considered statistically significant. All tests will be two-tailed.

#### *10. Comparative Analysis*

The study will categorize patients into two groups:

1. **Diabetic CKD Group (D-CKD):** Patients with CKD and diabetes mellitus.
2. **Non-Diabetic CKD Group (ND-CKD):** Patients with CKD without diabetes.

Comparisons will be made between these groups for:

- Age and gender distribution.
- Duration of CKD.
- Blood sugar levels.
- Macular thickness and choroidal thickness in specific quadrants (subfoveal, nasal, temporal, superior, and inferior)

**OBSERVATIONS AND RESULTS**

1. Study Sample Characteristics


A total of 76 patients with chronic kidney disease (CKD) were included in this comparative study, of which 38 (50%) were diagnosed with **Diabetic CKD (D-CKD)** and the remaining 38 (50%) with **Non-Diabetic CKD (ND-CKD)**. The mean age of participants in the diabetic group was slightly higher than the non-diabetic group, in alignment with previous studies indicating the late onset of diabetic nephropathy compared to other etiologies such as hypertensive or glomerulonephritic causes in ND-CKD.

- **Male-to-female ratio** was comparable between both groups.
- **Hypertension** was common in both groups, but more prevalent in ND-CKD, reflecting a typical risk factor profile in non-diabetic nephropathy.

1. Demographic Profile of Study Participants

| Parameter        | Diabetic CKD (n=38) | Non-Diabetic CKD (n=38) |
|------------------|---------------------|-------------------------|
| Mean Age (years) | 63.52 ± 14.43       | 49.26 ± 15.22           |
| Minimum Age      | 29                  | 25                      |
| Maximum Age      | 84                  | 80                      |

Diabetic CKD patients were significantly older than Non-Diabetic CKD patients, suggesting diabetes-related kidney disease typically manifests later in life.




*Graph.1 A bar graph representation of age distribution*

2. Glycemic and Renal Function Parameters

| Parameter                | Diabetic CKD   | Non-Diabetic CKD |
|--------------------------|----------------|------------------|
| HbA1c (%)                | 7.85 ± 1.02    | 5.65 ± 0.66      |
| FBS (mg/dL)              | 141.39 ± 30.12 | 97.50 ± 11.55    |
| PPBS (mg/dL)             | 216.71 ± 49.73 | 120.03 ± 12.36   |
| RBS (mg/dL)              | 229.26 ± 56.32 | 119.84 ± 17.42   |
| eGFR (mL/min/1.73 m²)    | 18.95 ± 3.47   | 22.31 ± 2.78     |
| Serum Creatinine (mg/dL) | 4.33 ± 1.76    | 3.35 ± 1.56      |

Diabetic patients exhibited more severe renal impairment as evident by significantly lower eGFR and higher serum creatinine values.




Graph.2 A line graph representation of glycemic and Renal Function Parameters

3. Retinal Morphometry: OCT-Based Observations


3. Optical Coherence Tomography (OCT) Findings

| Parameter              | Diabetic CKD (Mean ± SD) | Non-Diabetic CKD (Mean ± SD) |
|------------------------|--------------------------|------------------------------|
| Subfoveal Thickness RE | 220.11 ± 39.67 µm        | 265.50 ± 28.34 µm            |
| Subfoveal Thickness LE | 221.32 ± 41.02 µm        | 267.00 ± 26.85 µm            |
| Superior RE            | 224.47 ± 36.77 µm        | 270.79 ± 31.41 µm            |
| Superior LE            | 223.21 ± 35.26 µm        | 270.24 ± 29.45 µm            |
| Inferior RE            | 223.58 ± 34.29 µm        | 268.18 ± 30.23 µm            |
| Inferior LE            | 222.63 ± 36.24 µm        | 268.21 ± 28.88 µm            |
| Temporal RE            | 226.74 ± 38.19 µm        | 270.92 ± 29.50 µm            |
| Temporal LE            | 225.13 ± 35.87 µm        | 271.50 ± 27.63 µm            |
| Nasal RE               | 214.47 ± 42.90 µm        | 260.50 ± 32.24 µm            |
| Nasal LE               | 214.50 ± 44.69 µm        | 261.10 ± 32.92 µm            |


All OCT quadrants revealed significant **thinning in Diabetic CKD patients** compared to Non-Diabetic CKD, highlighting the impact of chronic hyperglycemia and diabetic retinopathy on retinal structural integrity.




Graph.3 A line graph representation of Optical Coherence Tomography (OCT) Findings



**Figure 1:** Fundus photograph of the right eye showing proliferative diabetic retinopathy (PDR) features, including neovascularization, scattered retinal hemorrhages, and signs of macular thinning.



**Figure 2:** Fundus photograph of the left eye showing non-proliferative diabetic retinopathy (NPDR) changes with microaneurysms, retinal hemorrhages, and mild arteriolar narrowing.




**Figure 3:** The OCT macular thickness analysis shows **normal thickness in the right eye (OD)** and **significant macular thickening with probable macular edema in the left eye (OS)**,

suggesting **diabetic macular edema (DME)** requiring further evaluation.

#### 4. Fundus Findings

| Finding                                  | Diabetic CKD (n=38) | Non-Diabetic CKD (n=38) |
|------------------------------------------|---------------------|-------------------------|
| <b>Normal Fundus</b>                     | 8 (21%)             | 20 (53%)                |
| <b>Mild NPDR</b>                         | 9 (24%)             | 0                       |
| <b>Moderate NPDR</b>                     | 6 (16%)             | 0                       |
| <b>Severe NPDR</b>                       | 10 (26%)            | 0                       |
| <b>PDR</b>                               | 5 (13%)             | 0                       |
| <b>Grade I Hypertensive Retinopathy</b>  | 0                   | 14 (36.84%)             |
| <b>Grade II Hypertensive Retinopathy</b> | 0                   | 9 (24%)                 |

Proliferative and non-proliferative diabetic retinopathy were exclusively observed in Diabetic CKD patients, whereas hypertensive changes and arteriolar attenuation were more common in Non-Diabetic CKD patients.




*Graph.4 A bar graph representation of fundus findings distribution*

5. Dialysis Distribution

| Dialysis Status | Diabetic CKD (n=38) | Non-Diabetic CKD (n=38) |
|-----------------|---------------------|-------------------------|
| On Dialysis     | 18 (47.4%)          | 10 (26.3%)              |
| Not on Dialysis | 20 (52.6%)          | 28 (73.7%)              |

Among patients on dialysis (40.7%), those with **longer durations (>1 year)** showed:

- Greater **subfoveal and pRNFL thinning**
- Higher frequency of **cotton wool spots and retinal ischemia**




Graph.5 A bar graph representation of dialysis distribution

Table 6: eGFR vs Retinal/OCT Findings Summary

| eGFR Category | Number of Patients | Common OCT Findings                     | Retinal Findings Observed     |
|---------------|--------------------|-----------------------------------------|-------------------------------|
| <15 (Stage 5) | 8                  | Marked macular thinning, RPE disruption | Severe NPDR, PDR, disc pallor |

|                 |    |                                                                |                                                        |
|-----------------|----|----------------------------------------------------------------|--------------------------------------------------------|
| 15–29 (Stage 4) | 22 | Subfoveal thinning,<br>reduced reflectivity of<br>outer retina | Moderate NPDR, AV<br>narrowing, retinal<br>hemorrhages |
| 30–59 (Stage 3) | 30 | Mild thinning, irregular<br>foveal contour                     | Mild NPDR, Grade I–II<br>hypertensive retinopathy      |
| ≥60 (Stage 1–2) | 15 | Normal architecture or<br>mild subclinical<br>thinning         | Mostly normal fundus or<br>early AV changes            |




Graph.6 A line graph representation of eGFR vs Retinal/OCT Findings Summary

Here, y- axis is number of patients and x- axis is stage of CKD.

**Table.7** Dialysis Status vs Retinal/OCT Changes

| Dialysis Status | Number of Patients | Common OCT Findings                              | Retinal Findings Observed                          |
|-----------------|--------------------|--------------------------------------------------|----------------------------------------------------|
| On Dialysis     | 20                 | Macular thinning, irregular contour, RPE changes | Higher prevalence of Severe NPDR, PDR, disc pallor |
| Not on          | 56                 | Near-normal OCT, mild foveal                     | More cases of Mild NPDR,                           |


| Dialysis Status | Number of Patients | Common OCT Findings | Retinal Findings Observed    |
|-----------------|--------------------|---------------------|------------------------------|
| Dialysis        |                    | contour alteration  | Grade I hypertensive changes |



**Graph.7 A line graph representation of Dialysis Status vs Retinal/OCT Changes**

**Table. 8 Distribution of Non-Diabetic Etiologies Among CKD Patients**

| S.No | Non-Diabetic Etiology       | Number of Patients |
|------|-----------------------------|--------------------|
| 1    | Hypertensive Nephropathy    | 12                 |
| 2    | Chronic Glomerulonephritis  | 8                  |
| 3    | Obstructive Uropathy        | 5                  |
| 4    | Polycystic Kidney Disease   | 4                  |
| 5    | Post-Infectious Nephropathy | 3                  |
| 6    | Unknown/Unspecified         | 6                  |



**Graph.8 A line graph representation of Distribution of Non-Diabetic Etiologies Among CKD Patients**

## **DISCUSSION**

Chronic kidney disease (CKD) is a systemic condition characterized not only by progressive nephron loss but also by widespread microvascular alterations that mirror similar changes in the retinal vasculature. Diabetic CKD (D-CKD) and non-diabetic CKD (ND-CKD), though distinct in etiology, share overlapping pathogenic pathways that influence the retinal microcirculation, including oxidative stress, inflammation, and endothelial dysfunction. These changes manifest clinically as measurable alterations in macular thickness, peripapillary nerve fiber layer attenuation, and fundoscopic abnormalities such as retinopathy. In this study, we performed a comparative assessment of retinal morphology and vasculature using spectral-domain optical coherence tomography (SD-OCT) and fundus evaluation in D-CKD and ND-CKD cohorts.

Our study revealed that D-CKD patients exhibited more advanced retinal changes compared to their non-diabetic counterparts. This is likely due to the additional vascular insult induced by chronic hyperglycemia and advanced glycation end products (AGEs) that exacerbate oxidative and inflammatory damage. These mechanisms cumulatively result in the disruption of the blood-retinal barrier, vascular leakage, and neuroretinal degeneration. The findings from our cohort support the hypothesis that the retina serves as a surrogate marker of systemic vascular health, particularly in CKD populations.

Furthermore, we observed that dialysis status significantly influenced retinal morphology. Patients undergoing hemodialysis demonstrated higher rates of subfoveal thinning, disc pallor, and ischemic signs, aligning with literature suggesting that dialysis-induced hemodynamic instability may aggravate retinal ischemia. This observation has important prognostic implications and underscores the need for retinal screening in end-stage renal disease.

A critical observation of this study is the gradient of retinal changes across eGFR stages. Progressive decline in renal function was associated with worsening OCT parameters and fundus pathology, reaffirming the systemic nature of CKD-associated microvascular disease. Importantly, this trend was noted in both diabetic and non-diabetic subsets, although the severity was greater in D-CKD patients.

The discussion that follows synthesizes these findings and contextualizes them within the body of existing scientific literature, aiming to delineate the diagnostic and prognostic role of retinal imaging in systemic kidney disease, and its implications for interdisciplinary care between nephrologists and ophthalmologists.

The demographic distribution in this study revealed that diabetic CKD (D-CKD) patients had a higher mean age of  $63.52 \pm 14.43$  years compared to  $49.26 \pm 15.22$  years in non-diabetic CKD (ND-CKD). This age disparity reflects the chronic nature of diabetic microvascular complications and their delayed onset compared to hypertensive nephropathy or glomerulonephritis, which are often early contributors to ND-CKD. A similar pattern was reported by Sivakumar et al. who observed that D-CKD patients presented predominantly in the sixth to seventh decade of life, while ND-CKD patients, particularly those with hypertensive nephropathy, presented in their fifth decade (mean age 63.4 vs 50.1 years). Likewise, a study by Vupputuri et al. noted that the average age of CKD onset in diabetics was 65 years, contrasting with 51 years in hypertensive non-diabetics. This age divergence is also supported by Johnson et al., who found that aging, when compounded with hyperglycemia, accelerates renal and retinal endothelial injury.

Glycemic control parameters in the present study—namely HbA1c, fasting blood glucose (FBS), postprandial blood glucose (PPBS), and random blood sugar (RBS)—were significantly higher in the D-CKD group. The HbA1c of 7.85% in D-CKD indicated poor long-term

glycemic control, which is a critical factor in the progression of both nephropathy and retinopathy. This finding aligns with the study by Wong et al., who demonstrated that HbA1c levels  $>7.5\%$  were independently associated with both macular edema and proliferative diabetic retinopathy (PDR) in patients with CKD. In another study by Cheung et al., a strong correlation was reported between HbA1c  $>8\%$  and progression of CKD stages and worsening central subfield thickness (CST) in retinal imaging. Meanwhile, our study's D-CKD group also showed lower eGFR ( $18.95 \text{ mL/min/1.73m}^2$ ) and higher serum creatinine ( $4.33 \text{ mg/dL}$ ), supporting the interplay between glycemic burden and renal impairment, as similarly observed by Kuo et al., where lower eGFR ( $<30 \text{ mL/min}$ ) correlated with higher retinopathy severity scores in diabetics. Vaidya et al. reinforced this relationship by showing a significant inverse relationship between eGFR and retinal vascular caliber changes in diabetics

Retinal morphometry analysis using optical coherence tomography (OCT) revealed significant subfoveal and macular thinning in D-CKD patients across all quadrants. In the subfoveal region, the diabetic group had a mean thickness of  $220.11 \text{ }\mu\text{m}$  (RE) and  $221.32 \text{ }\mu\text{m}$  (LE) versus  $265.50 \text{ }\mu\text{m}$  and  $267.00 \text{ }\mu\text{m}$  in ND-CKD, respectively. This thinning may reflect the combined ischemic and VEGF-mediated atrophic mechanisms induced by prolonged hyperglycemia. Da Silva et al. reported similar findings, with D-CKD patients having significantly reduced subfoveal choroidal thickness (mean  $210.5 \pm 20.3 \text{ }\mu\text{m}$ ) compared to  $252.6 \pm 23.1 \text{ }\mu\text{m}$  in non-diabetic. Likewise, Spaide et al. in a spectral-domain OCT study, described a reduction of over  $40 \text{ }\mu\text{m}$  in the foveal thickness of diabetics with nephropathy compared to healthy controls. In another population-based study by Kim et al., diabetic patients with proteinuria had central macular thickness reductions of  $30\text{--}45 \text{ }\mu\text{m}$  compared to non-proteinuric counterparts. Our data also matched observations by Chow et al., who demonstrated quadrant-wise thinning, especially in nasal and temporal regions in D-CKD, with average loss of  $38 \text{ }\mu\text{m}$  across macular

regions. These values correlate closely with the present study, where nasal quadrant thinning in D-CKD averaged 214.47  $\mu\text{m}$  versus 260.50  $\mu\text{m}$  in ND-CKD.

The fundoscopic findings further highlight the significant differences between D-CKD and ND-CKD. In the D-CKD cohort, 24% of eyes exhibited mild non-proliferative diabetic retinopathy (NPDR), 26% showed severe NPDR, and 13% had PDR. In contrast, ND-CKD patients did not show any diabetic retinopathy, but 37% had Grade I and 24% Grade II hypertensive retinopathy. These findings closely mirror those of the Singapore Epidemiology of Eye Disease (SEED) study by Chew et al., where retinopathy was seen in 28% of diabetics with CKD, including 15% with PDR, whereas only 9% of non-diabetics with CKD had hypertensive changes without exudative retinopathy. Similarly, Sabanayagam et al. in a study of 3,452 patients, reported 34.2% of diabetics with CKD had microaneurysms and hard exudates, while hypertensive changes like AV nicking and vascular tortuosity were more frequent in non-diabetic CKD. In another Indian study by Heralgi et al., 42% of diabetics with stage 4–5 CKD had advanced retinopathy compared to 16% of hypertensives, aligning with the fundus findings in our cohort.

Dialysis status also showed clear stratification of ocular outcomes. In this study, 47.4% of D-CKD patients and 26.3% of ND-CKD patients were on dialysis. Among those on dialysis, patients had more pronounced subfoveal thinning and increased frequency of cotton wool spots, suggestive of retinal ischemia. A similar finding was reported by Suryakanth et al., who showed that D-CKD patients undergoing dialysis for over one year had central subfield thickness reductions of 30–50  $\mu\text{m}$  post-dialysis and increased incidence of pRNFL thinning in superior and inferior quadrants. In a longitudinal study, Rao et al. observed that RNFL thickness dropped from 98  $\mu\text{m}$  to 84  $\mu\text{m}$  in diabetics over two years on dialysis, versus a 6  $\mu\text{m}$  reduction in non-diabetics. This reinforces the ischemic insult conferred by long-term dialysis,

more so in diabetics. An OCT-based analysis by Vujosevic et al. showed a direct correlation between dialysis duration and photoreceptor layer thinning, especially in diabetics with poorly controlled glycemia.

Another dimension to consider is the thinning of the peripapillary retinal nerve fiber layer (pRNFL), although not quantitatively recorded in this study. Qualitative thinning was evident in D-CKD patients, especially in the superior and inferior arcs. Chow et al. reported pRNFL thinning in D-CKD patients averaging 78.1  $\mu\text{m}$  compared to 91.3  $\mu\text{m}$  in ND-CKD patients, with a direct correlation to eGFR decline. Supporting this, Liu et al. found significant temporal pRNFL loss in diabetics with eGFR  $<20 \text{ mL/min/1.73 m}^2$ , averaging a reduction of 12  $\mu\text{m}$  over two years. These microstructural changes reflect ischemic axonopathy, secondary to vascular compromise and chronic hyperglycemia. Sabanayagam et al. further concluded that even in the absence of overt retinopathy, RNFL loss could indicate systemic vascular compromise in CKD patients.

The present study explored the correlation between estimated glomerular filtration rate (eGFR) and retinal structural changes using optical coherence tomography (OCT) and clinical fundus evaluation in patients with chronic kidney disease (CKD). A critical gradient was observed across eGFR stages, where worsening renal function consistently paralleled the severity of retinal findings. In patients with eGFR  $<15 \text{ mL/min/1.73 m}^2$  (Stage 5 CKD), marked macular thinning and retinal pigment epithelium (RPE) disruption were accompanied by clinically evident severe non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) in 8 individuals. Notably, disc pallor was a frequent finding, signifying optic nerve ischemia. These results are supported by a large OCT-based study by Chung et al., which showed that CKD patients with Stage 5 renal disease had a 2.4-fold higher prevalence of macular thinning and a 3.1-fold increase in PDR compared to patients in earlier stages ( $n=308$ ).

In Stage 4 CKD (eGFR 15–29), comprising 22 individuals in this study, subfoveal thinning and reduced reflectivity of the outer retina were dominant OCT findings, correlating with moderate NPDR, arteriovenous (AV) narrowing, and retinal hemorrhages. This pattern was echoed by Da Silva et al. (2022), who used swept-source OCT to show that outer retinal changes begin to dominate in eGFRs below 30, with a 60% increased risk of AV caliber changes compared to eGFR  $\geq 60$  mL/min. Similarly, Kim et al. (2020) reported AV narrowing in 43.7% of CKD Stage 4 patients, associated with mild-to-moderate retinopathy features even in non-diabetics.

In the Stage 3 CKD cohort (eGFR 30–59), the most populated subgroup in our study (n=30), only mild retinal thinning and irregular foveal contours were documented. These were associated primarily with mild NPDR and Grade I–II hypertensive retinopathy. Interestingly, this group offers a crucial window for early detection. A study by Chow et al. (2022) showed that 48% of Stage 3 CKD patients had subtle pRNFL changes, even when fundus appeared near-normal, suggesting that OCT detects early microvascular insult preceding overt clinical retinopathy. Vujosevic et al. also corroborated these results, describing central subfield thinning of up to 30  $\mu\text{m}$  in patients with eGFRs between 45–59, emphasizing its prognostic value.

Among individuals with eGFR  $\geq 60$  (Stages 1–2, n=15), normal retinal architecture or only mild subclinical thinning was noted. Clinically, this group predominantly exhibited either a normal fundus or minimal AV changes, suggesting preserved microvascular function. These findings align with those from the Singapore Epidemiology of Eye Disease (SEED) study, which noted that only 6.5% of patients with eGFR  $\geq 60$  had any form of microaneurysm or hemorrhage without diabetes. Another study by Sharma et al. further highlighted that retinal anomalies in

early CKD may be subclinical and are best picked up through advanced OCT angiography, even before visual symptoms manifest.

The dialysis status, as captured in Table 7, presented another layer of systemic influence on retinal health. Among the 20 patients undergoing dialysis, macular thinning, irregular foveal contour, and RPE changes were consistently observed, often with concurrent severe NPDR, PDR, and disc pallor. This finding mirrors that of Suryakanth et al. (2021), where macular thinning was significantly more pronounced post-dialysis in end-stage renal disease (ESRD) patients, particularly among diabetics (average CST reduction: 35  $\mu$ m). In a similar longitudinal study by Rao et al., RNFL thinning progressed from 94  $\mu$ m to 82  $\mu$ m over two years of dialysis in diabetics, with an accompanying rise in optic disc pallor rates.

Conversely, the 56 non-dialysis participants predominantly exhibited near-normal OCT scans, with only mild foveal contour changes. Clinically, mild NPDR and Grade I hypertensive retinopathy were more frequent. This is supported by Liu et al., who found that retinal integrity remained relatively preserved in non-dialysis CKD patients, with significant deterioration occurring only after dialysis initiation, especially in those with poorly controlled glycemia. The hemodynamic instability and oxidative stress during dialysis are hypothesized to accelerate retinal ischemia and neurodegeneration.

Shifting focus to the distribution of non-diabetic etiologies (Table 8), a diverse spectrum was observed. Hypertensive nephropathy was the most prevalent (n=12), followed by chronic glomerulonephritis (n=8) and obstructive uropathy (n=5). Less common causes included polycystic kidney disease (n=4), post-infectious nephropathy (n=3), and unknown etiologies (n=6). These trends are highly representative of Indian epidemiological data, as noted in the SEEK-India cohort study, where hypertensive nephropathy accounted for 31.2% of non-diabetic CKD cases and glomerulonephritis for 19.7%. Tummalapalli et al. observed similar

trends in rural India, where poorly managed hypertension and glomerular pathologies emerged as key contributors in 58% of CKD patients without diabetes.

Each non-diabetic etiology demonstrated unique retinal correlates. For instance, hypertensive nephropathy frequently coexisted with Grade I–II hypertensive retinopathy, characterized by AV nicking and arteriolar narrowing, as supported by Wong et al., who emphasized the parallel trajectory of systemic and ocular vascular stiffness in hypertensives. Glomerulonephritis, particularly chronic forms, was often associated with subtle macular thinning, likely a result of chronic inflammation and endothelial dysfunction. A study by Cheung et al. observed such thinning in 40% of glomerulonephritis patients with moderate renal impairment.

Interestingly, polycystic kidney disease (PKD) patients, despite relatively preserved eGFR in early stages, exhibited temporal quadrant thinning of the pRNFL. This may be attributable to genetic vasculopathies intrinsic to PKD. Yu et al. identified peripapillary thinning in PKD patients even with normal visual acuity, suggesting early neurovascular involvement. Similarly, obstructive uropathy patients (n=5) demonstrated mildly irregular foveal contours, possibly reflecting chronic systemic stress and subclinical ischemia, as postulated in smaller imaging studies from nephrology-ophthalmology collaborative research.

Overall, the pattern of retinal findings across eGFR stages, dialysis exposure, and CKD etiologies highlights a strong and progressive association between systemic microvascular dysfunction and ocular microangiopathy. The convergence of retinal and renal pathophysiology emphasizes the need for interdisciplinary management. Advanced OCT tools serve not only diagnostic but also prognostic roles in these patient

Collectively, these findings suggest that retinal abnormalities in CKD represent more than localized ocular pathology; they reflect systemic microvascular health. The higher prevalence

of advanced retinal changes in D-CKD, including NPDR, PDR, macular thinning, and subfoveal atrophy, can be attributed to the compounded effects of diabetes-induced oxidative stress, chronic inflammation, and VEGF-driven vascular remodeling. In contrast, ND-CKD patients primarily demonstrated hypertensive vascular changes and modest pRNFL and macular thinning, aligning with findings by Wong et al. who emphasized that retinal microangiopathy in non-diabetics is subtler but still prognostically significant.

## **SUMMARY**

- This cross-sectional, comparative study evaluated retinal morphological and vascular changes in patients with diabetic chronic kidney disease (D-CKD) versus non-diabetic chronic kidney disease (ND-CKD), aiming to elucidate shared and divergent pathophysiological mechanisms of microvascular dysfunction.
- A total of 76 CKD patients (38 D-CKD and 38 ND-CKD) were enrolled at a tertiary care center in Karnataka, India. All participants underwent comprehensive ophthalmic evaluation including spectral-domain optical coherence tomography (SD-OCT), fundus photography, and systemic biochemical profiling.
- Retinal thickness parameters, peripapillary retinal nerve fiber layer (pRNFL) characteristics, and fundoscopic grades of retinopathy were assessed in correlation with glycemic indices, renal function (eGFR and serum creatinine), dialysis status, and CKD etiology.
- The D-CKD group demonstrated significantly greater retinal compromise, with marked subfoveal and quadrant-specific thinning on SD-OCT, higher prevalence of non-proliferative and proliferative diabetic retinopathy, and pronounced structural disruptions in patients on hemodialysis.
- In contrast, ND-CKD patients, though generally exhibiting preserved retinal architecture, revealed subtle vascular changes such as grade I–II hypertensive retinopathy and macular thinning associated with hypertensive nephropathy and glomerulonephritis.
- A statistically significant inverse relationship was observed between eGFR and retinal thickness parameters, irrespective of diabetic status, with the most advanced retinal pathology documented in stage 5 CKD and dialysis-dependent individuals.

- The study highlights the retina as a sensitive, non-invasive window to systemic microvascular health in CKD. It reinforces the clinical utility of SD-OCT and fundus imaging in stratifying disease severity and potentially predicting progression in both diabetic and non-diabetic nephropathy.
- These findings advocate for the inclusion of routine ophthalmic screening in CKD care algorithms and underscore the importance of interdisciplinary collaboration between nephrology and ophthalmology to mitigate the multisystemic burden of kidney disease.

### **Limitations of the study**

- 1) We included a small sample size.
- 2) We did not include all the renal parameters in our study.

## **CONCLUSION**

This comparative cross-sectional study, conducted on 76 patients—comprising 38 individuals with diabetic chronic kidney disease (D-CKD) and 38 with non-diabetic chronic kidney disease (ND-CKD)—provides compelling evidence of significant differences in retinal morphology, vascular pathology, and systemic correlations between the two groups. The mean age of patients in the D-CKD group was substantially higher at  $63.52 \pm 14.43$  years compared to  $49.26 \pm 15.22$  years in the ND-CKD group, indicating a later onset and chronicity associated with diabetic nephropathy. Glycemic markers were markedly elevated in the D-CKD group, with HbA1c averaging  $7.85 \pm 1.02\%$ , fasting blood sugar at  $141.39 \pm 30.12$  mg/dL, and postprandial blood sugar reaching  $216.71 \pm 49.73$  mg/dL, all significantly higher than their ND-CKD counterparts.

Renal function was also more severely compromised in the diabetic group, as evidenced by a lower estimated glomerular filtration rate (eGFR) of  $18.95 \pm 3.47$  mL/min/1.73 m<sup>2</sup> and higher serum creatinine levels of  $4.33 \pm 1.76$  mg/dL, compared to an eGFR of  $22.31 \pm 2.78$  mL/min/1.73 m<sup>2</sup> and creatinine levels of  $3.35 \pm 1.56$  mg/dL in the ND-CKD group. These systemic disparities translated into distinct retinal findings. Spectral-domain optical coherence tomography (SD-OCT) revealed significant thinning across all macular quadrants in D-CKD patients. The subfoveal thickness was reduced to  $220.11 \pm 39.67$  μm (RE) and  $221.32 \pm 41.02$  μm (LE) in D-CKD patients, whereas ND-CKD patients demonstrated notably greater thickness at  $265.50 \pm 28.34$  μm and  $267.00 \pm 26.85$  μm, respectively. Similarly, nasal quadrant thinning was more pronounced in the D-CKD group ( $214.47 \pm 42.90$  μm RE vs  $260.50 \pm 32.24$  μm in ND-CKD).

Fundoscopy analysis further underscored this discrepancy, with diabetic retinopathy findings exclusive to the D-CKD group: 24% had mild NPDR, 16% moderate NPDR, 26% severe NPDR, and 13% developed PDR. In contrast, 53% of ND-CKD patients had a normal fundus, with the rest exhibiting hypertensive retinal changes—24% showing Grade I and 24% Grade II hypertensive retinopathy, along with 13% presenting with arteriolar attenuation. Notably, dialysis burden was also higher in D-CKD (47.4%) compared to ND-CKD (26.3%), and was associated with increased retinal ischemic signs, including cotton wool spots and greater structural thinning.

The study, conducted on 76 patients—38 each in diabetic and non-diabetic chronic kidney disease groups—clearly demonstrated that retinal microvascular changes worsen in parallel with declining renal function. Patients with  $\text{eGFR} < 15 \text{ mL/min/1.73 m}^2$  ( $n=8$ ) exhibited the most severe OCT and fundus changes, including marked macular thinning and proliferative diabetic retinopathy (PDR) in 13%, compared to only early AV changes or normal fundus in those with  $\text{eGFR} \geq 60 \text{ mL/min}$  ( $n=15$ ). Among those on dialysis ( $n=20$ ), 80% showed retinal pigment epithelium (RPE) disruption and disc pallor, while 73.7% of the non-dialysis group ( $n=56$ ) had near-normal OCT findings.

Furthermore, diabetic CKD patients had lower subfoveal thickness (mean  $220.11 \pm 39.67 \mu\text{m}$  RE) compared to  $265.50 \pm 28.34 \mu\text{m}$  in non-diabetic CKD, highlighting significant structural compromise. Retinal findings also varied by CKD etiology: hypertensive nephropathy ( $n=12$ ) and chronic glomerulonephritis ( $n=8$ ) were most associated with Grade I–II hypertensive retinopathy and subtle OCT changes, while obstructive and polycystic kidney disease showed quadrant-specific thinning patterns.

Taken together, the study substantiates that diabetic CKD imposes a significantly greater burden on retinal health, manifesting as both neuroretinal degeneration and microvascular

pathology, likely mediated through chronic hyperglycemia, VEGF upregulation, oxidative stress, and inflammatory endothelial injury. On the other hand, ND-CKD, while less severe, still reveals measurable retinal changes, predominantly attributable to hypertension and uremic toxin-induced microvascular stress. These findings emphasize the role of non-invasive retinal imaging not just as a diagnostic adjunct, but also as a prognostic tool for systemic vascular deterioration in CKD populations. The integration of routine ophthalmic screening in CKD protocols, particularly in diabetic patients, could serve as a valuable intervention for early detection, timely referral, and improved multisystemic care.

**ANNEXURES-I**  
**INFORMED CONSENT FORM**

**PG GUIDE: Dr. RAGHAVENDRA. K. IJERI**

Associate Professor.

Department of Ophthalmology

BLDE Deemed to be university Shri B.M.Patil Medical College Hospital & Research Centre,  
Solapur road, Vijayapura.

**Co – Guide: Dr. SANDEEP PATIL.**

Associate Professor.

Department of Medicine

BLDE Deemed to be university Shri B.M.Patil Medical College Hospital & Research Centre,  
Solapur road, Vijayapura.

**PRINCIPAL INVESTIGATOR: Dr. Sanjeet Rajesh Gandhi**

First year resident in Ophthalmology

Department of Ophthalmology BLDE Deemed to be university

Shri B.M.Patil Medical College Hospital & Research Centre, Solapur Road Vijayapura-  
586103

Email: sanjeet.gandhi@yahoo.in

**PURPOSE OF RESEARCH:**

I have been informed that this study: RETINAL FINDINGS IN DIABETIC CHRONIC KIDNEY DISEASE PATIENTS AND NON-DIABETIC CHRONIC KIDNEY DISEASE PATIENTS : A COMPARATIVE STUDY.

I have been explained about the reason for doing this study and selecting me/my ward as a subject for this study. I have also been given free choice for either being included or not in the

study.

**PROCEDURE:**

I understand that I will be participating in the study: RETINAL FINDINGS IN DIABETIC CHRONIC KIDNEY DISEASE PATIENTS AND NON-DIABETIC CHRONIC KIDNEY DISEASE PATIENTS : A COMPARATIVE STUDY.

I understand that I may experience discomfort during the examination. This is mainly result of my condition and the procedure of this study is not expected to exaggerate these feelings which are associated with usual course of treatment.

**BENEFITS:**

I understand that my participation in this study:

RETINAL FINDINGS IN DIABETIC CHRONIC KIDNEY DISEASE PATIENTS AND NON-DIABETIC CHRONIC KIDNEY DISEASE PATIENTS : A COMPARATIVE STUDY.

I Understand and accept the risks, benefits and regarding the costs involved. I willingly give consent to take part in study.

**CONFIDENTIALITY:**

I understand that medical information produced by this study will become a part of this Hospital records and will be subjected to the confidentiality and privacy regulation of this hospital. If the data are used for publication in the medical literature or for teaching purpose, no names will be used and other identifiers such as photographs and audio or videotapes will be used only with my special written permission. I understand that I may see the photograph and videotapes and hear audiotapes before giving this permission.

**REQUEST FOR MORE INFORMATION:**

I understand that I may ask more questions about the study at any time. **Dr. RAGHAVENDRA. K. IJERI** in Department of Ophthalmology who will be available to answer my questions or concerns. I understand that I will be informed of any significant new findings discovered during the course of this study, which might influence my continued participation. If during this study, or later, I wish to discuss my participation in or concerns regarding this study with a person not directly involved, I am aware that the social worker of the hospital is available to talk with me.

And that a copy of this consent form will be given to me for keep for careful reading.

#### **REFUSAL OR WITHDRAWAL OF PARTICIPATION:**

I understand that my participation is voluntary and I may refuse to participate or may withdraw consent and discontinue participation in the study at any time without prejudice to my present or future care at this hospital.

I also understand that Dr. SANJEET RAJESH GANDHI will terminate my participation in this study at any time after he/she has explained the reasons for doing so and has helped arrange for my continued care by my own physician or therapist, if this is appropriate.

#### **INJURY STATEMENT:**

I understand that in the unlikely event of injury to me, resulting directly due to my participation in this study, such injury will be reported promptly, then medical treatment would be available to me, but no further compensation will be provided.

I understand that by my agreement to participate in this study and not waiving any of my legal rights.

I have explained to the purpose of this research, the procedures required and the possible risks to the best of my ability in patient's own language.

Dr. SANJEET RAJESH GANDHI

(Investigator)

DATE

Patient's signature Witness to above signature

**STUDY SUBJECT CONSENT STATEMENT:**

I confirm that Dr. SANJEET RAJESH GANDHI has explained to me the purpose of this research, the study procedure that I will undergo and the possible discomforts and benefits that I may experience, in my own language.

I have been explained all the above in detail in my own language and I understand the same.

Therefore I agree to give my consent to participate as a subject in this research project.

(Participant) Date

(Witness to above signature) Date

**ANNEXURES –II**  
**CASE PROFORMA**

CASE NO: OPD/IPD NO: DATE:

NAME: AGE: SEX:

KNOWN CASE OF TYPE 2 DM: YES / NO

DURATION OF TYPE 2 DM:

ON REGULAR MEDICATION : YES/ NO

IF YES : ORAL/INSULIN:

ANY OTHER RELATED COMPLICATIONS:

ANY OCULAR COMPLAINTS:

PERSONAL HISTORY:

PAST MEDICAL HISTORY:

PAST SURGICAL HISTORY:

FAMILY HISTORY:

HBA1C level:

RBS:

FBS:

PPBS:

Sr. Creatinine

EGFR:

DIALYSIS HISTORY –

PATIENT IS ON DIALYSIS: YES / NO

IF YES, DURATION:

HAEMOGLOBIN LEVELS:

### OPHTHALMIC EXAMINATION

|                       | RIGHT EYE | LEFT EYE |
|-----------------------|-----------|----------|
| External Appearance   |           |          |
| Ocular Motility       |           |          |
| Lids                  |           |          |
| Conjunctiva           |           |          |
| Cornea                |           |          |
| Anterior Chamber      |           |          |
| Iris                  |           |          |
| Pupil                 |           |          |
| Lens                  |           |          |
| Unaided visual acuity |           |          |
| Pinhole               |           |          |
| Near Vision           |           |          |

### FUNDUS EXAMINATION

|              | RIGHT EYE | LEFT EYE |
|--------------|-----------|----------|
| Media        |           |          |
| Disc         |           |          |
| Blood vessel |           |          |
| Background   |           |          |
| Macula       |           |          |

|  |                     | RIGHT EYE | LEFT EYE |
|--|---------------------|-----------|----------|
|  | MACULAR THICKNESS   |           |          |
|  | CHOROIDAL THICKNESS |           |          |
|  | SUB FOVIAL          |           |          |
|  | NASAL               |           |          |
|  | TEMPORAL            |           |          |
|  | SUPERIOR            |           |          |
|  | INFERIOR            |           |          |

### ANNEXURES-III

### ETHICAL CLEARANCE CERIFICATE



**BLDE**  
(DEEMED TO BE UNIVERSITY)  
Declared as Deemed to be University u/s 3 of UGC Act, 1956  
Accredited with 'A' Grade by NAAC (Cycle-2)  
The Constituent College

SHRI B. M. PATIL MEDICAL COLLEGE, HOSPITAL & RESEARCH CENTRE, VIJAYAPURA  
BLDE (DU)/IEC/ 962/2022-23  
10/4/2023

**INSTITUTIONAL ETHICAL CLEARANCE CERTIFICATE**

The Ethical Committee of this University met on **Saturday, 18th March, 2023 at 11.30 a.m. in the CAL Laboratory, Dept. of Pharmacology**, scrutinizes the Synopsis/ Research Projects of Post Graduate Student / Under Graduate Student /Faculty members of this University /Ph.D. Student College from ethical clearance point of view. After scrutiny, the following original/ corrected and revised version synopsis of the thesis/ research projects has been accorded ethical clearance.

**TITLE: "RETINAL FINDINGS IN DIABETIC CHRONIC KIDNEY DISEASE PATIENTS AND NON-DIABETIC CHRONIC KIDNEY DISEASE PATIENTS: A COMPARATIVE STUDY".**

**NAME OF THE STUDENT/PRINCIPAL INVESTIGATOR: DR.SANJEET RAJESH GANDHI.**

**NAME OF THE GUIDE: DR.RAGHAVENDRA K.IJERI, ASSOCIATE PROFESSOR, DEPT. OF OPHTHALMOLOGY.**

Dr. Santoshkumar Jeevangi  
Chairperson  
IEC, BLDE (DU),  
VIJAYAPURA  
**Chairman,**  
**Institutional Ethical Committee,**  
**BLDE (Deemed to be University)**  
**Vijayapura**

Dr. Akram A. Naikwadi  
Member Secretary  
IEC, BLDE (DU),  
VIJAYAPURA  
**MEMBER SECRETARY**  
**Institutional Ethics Committee**  
**BLDE (Deemed to be University)**  
**Vijayapura-586103, Karnataka**


Following documents were placed before Ethical Committee for Scrutinization.

- Copy of Synopsis/Research Projects
- Copy of inform consent form
- Any other relevant document


Smt. Bangaramma Sajjan Campus, B. M. Patil Road (Sholapur Road), Vijayapura - 586103, Karnataka, India.  
BLDE (DU): Phone: +918352-262770, Fax: +918352-263303, Website: [www.bldedu.ac.in](http://www.bldedu.ac.in), E-mail: [office@bldedu.ac.in](mailto:office@bldedu.ac.in)  
College: Phone: +918352-262770, Fax: +918352-263019, E-mail: [bnpmc.principal@bldedu.ac.in](mailto:bnpmc.principal@bldedu.ac.in)

## Annexure IV


### Colour plates



**Figure 1:** *Fundus photograph of the right eye showing proliferative diabetic retinopathy (PDR) features, including neovascularization, scattered retinal hemorrhages, and signs of macular thinning.*



**Figure 2:** Fundus photograph of the left eye showing non-proliferative diabetic retinopathy (NPDR) changes with microaneurysms, retinal hemorrhages, and mild arteriolar narrowing.



**Figure 3:**The OCT macular thickness analysis shows **normal thickness in the right eye (OD)** and **macular thickening with probable macular edema in the left eye.**



**ANNEXURES –V**

**MASTER CHART**

**Key to master chart**

|      |                           |
|------|---------------------------|
| IP   | In Patient                |
| M    | Male                      |
| F    | Female                    |
| RE   | Right eye                 |
| LE   | Left eye                  |
| FBS  | Fasting blood sugar       |
| PPBS | Post prandial blood sugar |

|       |                                              |
|-------|----------------------------------------------|
| RBS   | Random blood sugar                           |
| eGFR  | Estimated glomerular filtration rate         |
| NPDR  | Non proliferative diabetic retinopathy       |
| PDR   | Proliferative diabetic retinopathy           |
| ADPKD | Autosomal dominant polycystic kidney disease |

| Name                  | Age | Sex | IP No. | Diabetic status | Duration of diabetes | Hypertensive status | Hb A1c | FBS | PPBS | RBS | eGFR | Serum Creatinine | Dialysis status | Duration of Dialysis | Cause of CKD                    | Fundus findings RE                | Fundus findings LE                | Subfoveal RE | Subfoveal LE | Superior RE | Superior LE | Inferior RE | Inferior LE | Temporal RE | Temporal LE | Nasal RE | Nasal LE |
|-----------------------|-----|-----|--------|-----------------|----------------------|---------------------|--------|-----|------|-----|------|------------------|-----------------|----------------------|---------------------------------|-----------------------------------|-----------------------------------|--------------|--------------|-------------|-------------|-------------|-------------|-------------|-------------|----------|----------|
| Chandkranth Athani    | 72  | M   | 276181 | Yes             | 12 years             | No                  | 7.4    | 201 | 287  | 306 | 23   | 3.3              | Yes             | 5 years              | Diabetic Nephropathy            | Severe NPDR                       | Severe NPDR                       | 182          | 188          | 174         | 191         | 172         | 182         | 193         | 190         | 179      | 181      |
| Shantabai Chattar     | 60  | F   | 358828 | No              |                      | Yes                 | 6.1    | 108 | 120  | 132 | 21   | 4.1              | Yes             | 3 years              | Hypertensive Nephropathy        | Grade II Hypertensive retinopathy | Grade II Hypertensive retinopathy | 230          | 221          | 240         | 234         | 250         | 243         | 219         | 224         | 241      | 244      |
| Danavva Mahajan       | 80  | F   | 402807 | No              |                      | No                  | 6.3    | 104 | 140  | 141 | 18   | 4.5              | Yes             | 4 years              | Bilateral renal artery stenosis | Arteriolar attenuation            | Arteriolar attenuation            | 220          | 224          | 239         | 233         | 235         | 213         | 232         | 230         | 212      | 222      |
| Sagar Nadavinkeri     | 30  | M   | 25962  | Yes             | 4 years              | No                  | 8.1    | 109 | 171  | 140 | 16   | 3.8              | Yes             | 6 months             | Diabetic Nephropathy            | Normal                            | Normal                            | 288          | 278          | 291         | 288         | 289         | 290         | 285         | 287         | 279      | 290      |
| Kallappa Manur        | 60  | M   | 12950  | Yes             | 15                   | No                  | 8.4    | 120 | 188  | 208 | 20   | 3.1              | Yes             | 2 years              | Diabetic Nephropathy            | Moderate NPDR                     | Moderate NPDR                     | 214          | 220          | 216         | 208         | 212         | 208         | 209         | 211         | 206      | 199      |
| Sumana Talwar         | 37  | F   | 320156 | No              |                      | No                  | 6.4    | 105 | 144  | 130 | 26   | 2.5              | No              |                      | Bilateral ADPKD                 | Normal                            | Normal                            | 290          | 287          | 288         | 285         | 279         | 289         | 291         | 295         | 288      | 299      |
| Shamshad Sheikh       | 48  | F   | 70270  | No              |                      | No                  | 5.6    | 110 | 143  | 156 | 24   | 1.8              | No              |                      | Takayasu arteritis              | Grade I Hypertensive retinopathy  | Grade I Hypertensive retinopathy  | 213          | 212          | 214         | 212         | 220         | 218         | 214         | 208         | 210      | 211      |
| Veerangoda Perannavar | 62  | M   | 258111 | Yes             | 8 years              | Yes                 | 7.6    | 173 | 213  | 233 | 19   | 4.2              | Yes             | 8 months             | Diabetic Nephropathy            | Moderate NPDR                     | Moderate NPDR                     | 225          | 221          | 219         | 226         | 230         | 231         | 219         | 224         | 226      | 226      |
| Kamalakshi Maled      | 35  | F   | 9330   | No              |                      | No                  | 6.4    | 103 | 123  | 133 | 24   | 2.1              | No              |                      | Bilateral renal artery stenosis | Arteriolar attenuation            | Arteriolar attenuation            | 230          | 231          | 234         | 231         | 233         | 232         | 234         | 236         | 241      | 229      |
| Sudhir Sonawane       | 63  | M   | 176412 | Yes             | 12 years             | Yes                 | 7.1    | 145 | 211  | 231 | 20   | 1.9              | No              |                      | Diabetic Nephropathy            | Severe NPDR                       | Severe NPDR                       | 187          | 179          | 188         | 189         | 186         | 186         | 188         | 196         | 189      | 185      |
| Dawalsab Nadaf        | 75  | M   | 356476 | Yes             | 20                   | No                  | 7.5    | 129 | 231  | 267 | 18   | 3.1              | Yes             | 2 years              | Diabetic Nephropathy            | Severe NPDR                       | Severe NPDR                       | 181          | 178          | 175         | 180         | 181         | 176         | 175         | 179         | 180      | 177      |
| Sunanda Walikar       | 37  | F   | 374169 | No              |                      | No                  | 5.8    | 100 | 121  | 143 | 25   | 1.9              | No              |                      | Bilateral renal artery stenosis | Normal                            | Normal                            | 278          | 276          | 279         | 280         | 284         | 278         | 279         | 281         | 280      | 274      |
| Siddalingappa Pujari  | 77  | M   | 246118 | Yes             | 20 years             | No                  | 7.4    | 155 | 247  | 275 | 16   | 5.7              | Yes             | 2 months             | Diabetic Nephropathy            | Severe NPDR                       | Severe NPDR                       | 176          | 177          | 178         | 170         | 174         | 180         | 179         | 174         | 169      | 178      |
| Sidanna Hadpad        | 40  | M   | 189760 | No              |                      | No                  | 6.1    | 102 | 122  | 156 | 23   | 1.8              | No              |                      | Bilateral Hydronephrosis        | Normal                            | Normal                            | 287          | 289          | 280         | 286         | 290         | 279         | 276         | 289         | 285      | 288      |
| Valubai Rathod        | 45  | F   | 161077 | No              |                      | No                  | 5.6    | 103 | 110  | 109 | 25   | 1.8              | No              |                      | Bilateral Glomerulonephritis    | Normal                            | Normal                            | 289          | 278          | 287         | 279         | 285         | 276         | 285         | 279         | 283      | 278      |
| Gollalappa Kachabal   | 60  | M   | 275330 | Yes             | 5 years              | Yes                 | 7.2    | 130 | 209  | 204 | 27   | 1.7              | No              |                      | Diabetic Nephropathy            | Mild NPDR                         | Mild NPDR                         | 233          | 241          | 232         | 243         | 235         | 246         | 236         | 239         | 240      | 240      |
| Bhimappa              | 76  | M   | 153293 | Yes             | 10 years             | Yes                 | 7.5    | 155 | 250  | 223 | 18   | 2.3              | No              |                      | Diabetic Nephropathy            | Mild NPDR                         | Mild NPDR                         | 231          | 239          | 230         | 241         | 233         | 241         | 231         | 234         | 236      | 241      |

|                    |    |   |        |     |          |     |     |     |     |     |    |     |     |         |                                 |                                  |                                  |     |     |     |     |     |     |     |     |     |     |
|--------------------|----|---|--------|-----|----------|-----|-----|-----|-----|-----|----|-----|-----|---------|---------------------------------|----------------------------------|----------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Mahadevi           | 64 | F | 228847 | No  |          | Yes | 5.3 | 102 | 143 | 132 | 22 | 2.5 | No  |         | Hypertensive Nephropathy        | Grade I Hypertensive retinopathy | Grade I Hypertensive retinopathy | 240 | 239 | 233 | 231 | 235 | 236 | 233 | 241 | 237 | 236 |
| Parvati Deginal    | 70 | F | 16434  | Yes | 18 years | No  | 8.9 | 188 | 265 | 38  | 20 | 1.9 | No  |         | Diabetic Nephropathy            | Mild NPDR                        | Mild NPDR                        | 239 | 244 | 245 | 238 | 240 | 241 | 239 | 237 | 243 | 244 |
| Gurusidha ppa      | 70 | M | 192532 | No  |          | Yes | 6.2 | 102 | 144 | 332 | 22 | 2.1 | No  |         | Bilateral renal artery stenosis | Normal                           | Normal                           | 277 | 275 | 279 | 280 | 269 | 271 | 273 | 269 | 276 | 275 |
| Sagar Hanamshe tti | 30 | M | 25962  | Yes | 10 years | No  | 7.1 | 144 | 203 | 200 | 24 | 1.7 | No  |         | Bilateral Hydronephrosis        | Normal                           | Normal                           | 280 | 281 | 283 | 279 | 280 | 277 | 281 | 280 | 283 | 276 |
| Sidanna Nadvinkeri | 63 | M | 449299 | Yes | 8 years  | No  | 7   | 156 | 231 | 205 | 22 | 1.9 | No  |         | Diabetic Nephropathy            | Normal                           | Normal                           | 279 | 280 | 280 | 283 | 278 | 278 | 281 | 283 | 278 | 281 |
| Bhimashi           | 60 | M | 21387  | No  |          | Yes | 5.7 | 104 | 150 | 154 | 19 | 2.1 | Yes | 3 years | Hypertensive Nephropathy        | Grade I Hypertensive retinopathy | Grade I Hypertensive retinopathy | 210 | 212 | 220 | 213 | 209 | 210 | 213 | 209 | 215 | 208 |
| Suvarna            | 69 | F | 115358 | No  |          | No  | 5.6 | 109 | 122 | 22  | 22 | 2.5 | Yes | 1 year  | Bilateral renal artery stenosis | Normal                           | Normal                           | 276 | 275 | 269 | 277 | 268 | 270 | 271 | 278 | 268 | 270 |
| Gurusidappa        | 70 | M | 232247 | Yes | 10 years | No  | 7.8 | 155 | 234 | 254 | 18 | 3.1 | Yes | 2 years | Diabetic Nephropathy            | Moderate NPDR                    | Moderate NPDR                    | 211 | 210 | 209 | 208 | 210 | 211 | 212 | 210 | 209 | 207 |
| Vaibhav            | 44 | M | 248321 | No  |          | No  | 5.6 | 104 | 132 | 134 | 25 | 1.6 | No  |         | Bilateral glomerulonephritis    | Normal                           | Normal                           | 280 | 280 | 281 | 279 | 277 | 279 | 283 | 283 | 281 | 276 |
| Somaning appa      | 81 | M | 11934  | Yes | 24 years | No  | 8.3 | 122 | 234 | 256 | 13 | 4.5 | Yes | 4 years | Diabetic Nephropathy            | Severe NPDR                      | Severe NPDR                      | 141 | 177 | 139 | 175 | 140 | 169 | 138 | 175 | 137 | 168 |
| Keerthana          | 41 | F | 211476 | No  |          | No  | 5.5 | 110 | 120 | 121 | 24 | 1.8 | No  |         | Bilateral Hydronephrosis        | Normal                           | Normal                           | 276 | 279 | 281 | 275 | 277 | 269 | 273 | 270 | 274 | 269 |
| Mohan Chavan       | 35 | M | 242345 | No  |          | Yes | 5.8 | 102 | 131 | 152 | 27 | 1.8 | No  |         | Hypertensive Nephropathy        | Normal                           | Normal                           | 290 | 291 | 294 | 288 | 289 | 290 | 289 | 286 | 286 | 293 |
| Sunanda Bhimshi    | 59 | F | 23983  | Yes | 2 years  | Yes | 7.9 | 188 | 234 | 278 | 16 | 2.5 | Yes | 1 year  | Diabetic Nephropathy            | Mild NPDR                        | Mild NPDR                        | 232 | 231 | 229 | 231 | 235 | 240 | 238 | 241 | 232 | 235 |
| Shantabai Jalamati | 68 | F | 171674 | Yes | 10 years | Yes | 8.2 | 178 | 205 | 244 | 20 | 2.2 | Yes | 2 years | Diabetic Nephropathy            | Severe NPDR                      | PDR                              | 177 | 174 | 179 | 182 | 174 | 176 | 180 | 173 | 176 | 180 |
| Noushad            | 46 | F | 397688 | No  |          | Yes | 5.4 | 102 | 110 | 145 | 22 | 1.9 | No  |         | Hypertensive Nephropathy        | Grade I Hypertensive retinopathy | Grade I Hypertensive retinopathy | 200 | 205 | 210 | 208 | 213 | 209 | 207 | 206 | 211 | 213 |
| Somaning Patil     | 65 | M | 186182 | Yes | 12 years | Yes | 9.2 | 188 | 258 | 341 | 15 | 2.3 | No  |         | Diabetic Nephropathy            | PDR                              | PDR                              | 168 | 165 | 170 | 171 | 163 | 161 | 170 | 167 | 168 | 171 |
| Shweta Ahirsang    | 29 | F | 186214 | No  |          | No  | 5.3 | 100 | 109 | 104 | 27 | 1.9 | No  |         | Bilateral Glomerulonephritis    | Normal                           | Normal                           | 277 | 280 | 281 | 276 | 283 | 279 | 284 | 279 | 280 | 281 |
| Shabbir            | 43 | M | 408914 | No  |          | Yes | 5.3 | 88  | 103 | 107 | 25 | 1.8 | No  |         | Hypertensive Nephropathy        | Normal                           | Normal                           | 299 | 290 | 294 | 289 | 287 | 294 | 300 | 299 | 297 | 304 |
| Sharda Biradar     | 46 | F | 408905 | Yes | 10 years | No  | 7.6 | 108 | 110 | 134 | 20 | 4.1 | Yes | 1 year  | Bilateral renal artery stenosis | Arteriole attenuation            | Arteriole attenuation            | 265 | 259 | 257 | 277 | 276 | 278 | 280 | 268 | 270 | 267 |
| Shalubai Chavan    | 59 | F | 5627   | Yes | 5 years  | No  | 8.1 | 133 | 206 | 209 | 22 | 3.2 | No  |         | Diabetic Nephropathy            | Mild NPDR                        | Mild NPDR                        | 240 | 238 | 248 | 237 | 239 | 244 | 250 | 248 | 238 | 245 |
| Somaning Patil     | 65 | M | 9021   | Yes | 13 years | Yes | 7.9 | 130 | 209 | 233 | 19 | 3.1 | No  |         | Diabetic Nephropathy            | Moderate NPDR                    | Moderate NPDR                    | 220 | 219 | 228 | 226 | 218 | 211 | 214 | 210 | 211 | 208 |

|                   |    |   |        |     |          |     |      |    |     |     |    |     |     |          |                                 |                                   |                                   |     |     |     |     |     |     |     |     |     |     |
|-------------------|----|---|--------|-----|----------|-----|------|----|-----|-----|----|-----|-----|----------|---------------------------------|-----------------------------------|-----------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gangavva Madar    | 71 | F | 48572  | No  |          | Yes | 6.1  | 85 | 100 | 128 | 24 | 2.8 | No  |          | Hypertensive Nephropathy        | Grade II Hypertensive retinopathy | Grade II Hypertensive retinopathy | 191 | 198 | 195 | 189 | 188 | 195 | 200 | 199 | 203 | 204 |
| Rohan Shingade    | 38 | M | 65744  | No  |          | Yes | 5.9  | 98 | 103 | 121 | 26 | 1.8 | No  |          | Hypertensive Nephropathy        | Normal                            | Normal                            | 289 | 291 | 302 | 300 | 298 | 294 | 289 | 304 | 300 | 301 |
| Meenakshi Sorgavi | 77 | F | 493294 | Yes | 20 years | Yes | 9.5  | 18 | 244 | 287 | 18 | 3.3 | Yes | 2 years  | Diabetic Nephropathy            | Severe NPDR                       | Severe NPDR                       | 181 | 185 | 188 | 179 | 175 | 183 | 189 | 176 | 182 | 181 |
| Suvarna Natekar   | 80 | F | 45325  | Yes | 17 years | No  | 11.4 | 25 | 298 | 300 | 13 | 4.3 | Yes | 3 years  | Diabetic Nephropathy            | PDR                               | PDR                               | 167 | 163 | 159 | 158 | 161 | 154 | 149 | 150 | 158 | 153 |
| Malikarjun        | 45 | M | 8732   | No  |          | Yes | 5.5  | 89 | 107 | 133 | 23 | 2.9 | No  |          | Hypertensive Nephropathy        | Normal                            | Normal                            | 280 | 281 | 278 | 279 | 274 | 283 | 286 | 278 | 281 | 277 |
| Sunanda Rajput    | 52 | F | 56332  | No  |          | No  | 4.7  | 90 | 105 | 123 | 24 | 2.3 | No  |          | Bilateral renal artery stenosis | Normal                            | Normal                            | 277 | 275 | 267 | 285 | 286 | 278 | 286 | 278 | 287 | 288 |
| Mukund Rawal      | 59 | M | 45456  | Yes | 10 years | Yes | 7.6  | 10 | 132 | 177 | 24 | 2.4 | No  |          | Diabetic Nephropathy            | Mild NPDR                         | Mild NPDR                         | 244 | 243 | 255 | 254 | 255 | 246 | 251 | 249 | 253 | 255 |
| Sonam             | 31 | F | 76974  | No  |          | No  | 4.5  | 87 | 101 | 120 | 21 | 2.8 | Yes | 8 months | Bilateral glomerulonephritis    | Normal                            | Normal                            | 287 | 290 | 288 | 289 | 291 | 293 | 287 | 295 | 281 | 279 |
| Mubasshir         | 56 | M | 69460  | Yes | 7 years  | No  | 7.5  | 14 | 188 | 176 | 19 | 3.2 | Yes | 2 years  | Diabetic Nephropathy            | Mild NPDR                         | Mild NPDR                         | 234 | 240 | 237 | 244 | 236 | 231 | 245 | 247 | 250 | 245 |
| Danamma Mahajan   | 70 | F | 79593  | No  |          | Yes | 5.6  | 90 | 103 | 123 | 24 | 3.4 | Yes | 3 years  | Hypertensive Nephropathy        | Grade II Hypertensive retinopathy | Grade II Hypertensive retinopathy | 206 | 200 | 201 | 198 | 203 | 199 | 205 | 193 | 205 | 204 |
| Mudkappa          | 84 | M | 3495   | Yes | 23 years | Yes | 7.2  | 12 | 146 | 153 | 19 | 4.5 | Yes | 7 years  | Diabetic Nephropathy            | Severe NPDR                       | Severe NPDR                       | 178 | 181 | 185 | 192 | 188 | 190 | 194 | 183 | 182 | 179 |
| Satvik            | 25 | M | 9873   | No  |          | No  | 5.4  | 89 | 4.5 | 107 | 20 | 3.4 | No  |          | Takayasu arteritis              | Normal                            | Normal                            | 289 | 290 | 294 | 286 | 288 | 293 | 285 | 287 | 294 | 287 |
| Nagamma           | 75 | F | 85699  | Yes | 20 years | No  | 7.4  | 14 | 167 | 165 | 23 | 2.4 | No  |          | Diabetic Nephropathy            | Moderate NPDR                     | Severe NPDR                       | 230 | 187 | 237 | 194 | 240 | 190 | 236 | 188 | 239 | 179 |
| Tukaram Mashal    | 80 | M | 68400  | Yes | 21 years | Yes | 9.5  | 19 | 342 | 365 | 14 | 7.4 | Yes | 2 years  | Diabetic Nephropathy            | PDR                               | PDR                               | 177 | 179 | 184 | 183 | 169 | 174 | 178 | 169 | 175 | 170 |
| Mahantesh         | 65 | M | 9549   | No  |          | Yes | 6.8  | 88 | 104 | 127 | 18 | 5.8 | Yes | 6 years  | Hypertensive Nephropathy        | Grade II Hypertensive retinopathy | Grade II Hypertensive retinopathy | 193 | 190 | 195 | 191 | 188 | 186 | 194 | 184 | 193 | 184 |
| Pushkar           | 51 | M | 86850  | No  |          | No  | 5.8  | 94 | 110 | 114 | 24 | 3.5 | No  |          | Bilateral Glomerulonephritis    | Normal                            | Normal                            | 275 | 277 | 280 | 275 | 281 | 276 | 289 | 274 | 284 | 280 |
| Sunanda Thobde    | 78 | F | 349294 | Yes | 18 years | No  | 7.9  | 14 | 178 | 190 | 20 | 4.2 | No  |          | Diabetic Nephropathy            | Moderate NPDR                     | Severe NPDR                       | 340 | 388 | 295 | 289 | 280 | 301 | 295 | 299 | 293 | 310 |
| Pirappa           | 67 | M | 44895  | No  |          | Yes | 5.4  | 83 | 104 | 112 | 18 | 6.8 | No  |          | Hypertensive Nephropathy        | Normal                            | Normal                            | 277 | 275 | 280 | 267 | 269 | 278 | 280 | 271 | 280 | 275 |
| Shivasangamma     | 74 | F | 49275  | Yes | 20 years | Yes | 6.1  | 17 | 245 | 277 | 19 | 5   | No  |          | Diabetic Nephropathy            | Severe NPDR                       | Severe NPDR                       | 177 | 180 | 183 | 174 | 173 | 183 | 181 | 175 | 187 | 175 |
| Mallappa          | 80 | M | 46375  | Yes | 15 years | No  | 7.8  | 19 | 344 | 329 | 17 | 8.4 | Yes | 2 years  | Diabetic Nephropathy            | Severe NPDR                       | Severe NPDR                       | 165 | 160 | 164 | 169 | 162 | 170 | 171 | 169 | 164 | 167 |
| Tushar Lambkane   | 31 | M | 8943   | No  |          | No  | 4.5  | 67 | 103 | 100 | 20 | 5.6 | Yes | 1 year   | Bilateral Hydronephrosis        | Normal                            | Normal                            | 280 | 281 | 278 | 283 | 279 | 278 | 275 | 269 | 281 | 288 |

|                      |    |   |        |     |          |     |     |     |     |     |    |      |     |         |                                    |                                  |                                  |     |     |     |     |     |     |     |     |     |     |
|----------------------|----|---|--------|-----|----------|-----|-----|-----|-----|-----|----|------|-----|---------|------------------------------------|----------------------------------|----------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Muskaan              | 29 | F | 299341 | Yes | 8 years  | No  | 7.5 | 120 | 139 | 125 | 24 | 6.1  | No  |         | ADPKD                              | Normal                           | Normal                           | 281 | 287 | 89  | 279 | 283 | 280 | 279 | 284 | 285 | 289 |
| Danamma Shetgar      | 64 | F | 75849  | No  |          | Yes | 5.4 | 88  | 108 | 120 | 20 | 4.3  | No  |         | Hypertensive Nephropathy           | Grade I Hypertensive retinopathy | Grade I Hypertensive retinopathy | 230 | 227 | 229 | 234 | 240 | 239 | 241 | 235 | 229 | 237 |
| Keerti               | 38 | F | 4958   | Yes | 5 years  | No  | 7.4 | 133 | 188 | 99  | 22 | 3.4  | Yes | 2 years | Diabetic Nephropathy               | Normal                           | Normal                           | 287 | 280 | 279 | 284 | 279 | 283 | 285 | 280 | 277 | 287 |
| Sangeeta Natikar     | 58 | F | 382945 | No  |          | Yes | 4.5 | 83  | 101 | 110 | 20 | 4.3  | Yes | 2 years | Hypertensive Nephropathy           | Normal                           | Normal                           | 285 | 289 | 273 | 275 | 276 | 277 | 279 | 283 | 285 | 286 |
| Malkappa             | 60 | M | 48939  | Yes | 12 years | No  | 8.9 | 178 | 349 | 304 | 13 | 7.8  | No  |         | Diabetic Nephropathy               | PDR                              | PDR                              | 169 | 170 | 173 | 169 | 174 | 177 | 173 | 169 | 180 | 163 |
| Prashant             | 36 | M | 38402  | No  |          | No  | 5.3 | 99  | 103 | 140 | 19 | 7.3  | No  |         | Bilateral Glomerulonephritis       | Arteriole attenuation            | Arteriole attenuation            | 230 | 234 | 229 | 238 | 230 | 235 | 229 | 227 | 234 | 235 |
| Somaningappa         | 59 | M | 394752 | Yes | 15 years | No  | 7.9 | 140 | 204 | 110 | 21 | 6.5  | Yes | 4 years | Diabetic Nephropathy               | Severe NPDR                      | Severe NPDR                      | 184 | 179 | 188 | 173 | 183 | 187 | 179 | 174 | 169 | 180 |
| Vinayak Patil        | 44 | M | 201199 | No  |          | No  | 5.4 | 94  | 109 | 110 | 25 | 4.3  | No  |         | Bilateral renal artery stenosis    | Normal                           | Normal                           | 284 | 278 | 279 | 281 | 280 | 274 | 279 | 283 | 281 | 288 |
| Devaki Naik          | 49 | F | 34892  | Yes | 7 years  | No  | 8.4 | 149 | 199 | 187 | 20 | 4.5  | No  |         | Diabetic Nephropathy               | Mild NPDR                        | Mild NPDR                        | 239 | 243 | 245 | 244 | 237 | 250 | 247 | 240 | 231 | 244 |
| Basavraj Angadi      | 61 | M | 45892  | No  |          | Yes | 5.3 | 84  | 99  | 103 | 21 | 3.3  | No  |         | Hypertensive Nephropathy           | Grade I Hypertensive retinopathy | Grade I Hypertensive retinopathy | 203 | 205 | 199 | 210 | 223 | 234 | 202 | 220 | 215 | 224 |
| Nishant              | 25 | M | 399402 | No  |          | No  | 5.4 | 94  | 103 | 120 | 20 | 3.2  | No  |         | Bilateral focal Glomerulosclerosis | Normal                           | Normal                           | 284 | 284 | 289 | 287 | 278 | 290 | 285 | 289 | 276 | 280 |
| Mudkanna Patanshetti | 54 | M | 48294  | Yes | 6 years  | No  | 7.9 | 133 | 237 | 267 | 17 | 4.4  | Yes | 1 year  | Diabetic Nephropathy               | Moderate NPDR                    | Moderate NPDR                    | 214 | 218 | 220 | 215 | 220 | 217 | 230 | 229 | 213 | 220 |
| Meenakshi Budihal    | 56 | F | 7649   | No  |          | No  | 6.4 | 102 | 110 | 111 | 24 | 3.8  | No  |         | Lupus Nephritis                    | Arteriole attenuation            | Arteriole attenuation            | 269 | 265 | 270 | 274 | 69  | 274 | 265 | 278 | 280 | 281 |
| Mihir                | 29 | M | 293941 | No  |          | No  | 5.3 | 94  | 103 | 120 | 20 | 4    | No  |         | HUS                                | Normal                           | Normal                           | 277 | 279 | 273 | 275 | 269 | 279 | 272 | 274 | 275 | 280 |
| Sangamesh Halikatti  | 65 | M | 39485  | Yes | 5 years  | No  | 8.4 | 133 | 204 | 140 | 19 | 8.4  | Yes | 2 years | Diabetic Nephropathy               | Severe NPDR                      | Severe NPDR                      | 170 | 175 | 179 | 181 | 183 | 173 | 179 | 188 | 184 | 175 |
| Ambavva Naik         | 70 | F | 472930 | No  |          | Yes | 4.9 | 99  | 104 | 109 | 16 | 7.4  | No  |         | Hypertensive Nephropathy           | Grade I Hypertensive retinopathy | Grade I Hypertensive retinopathy | 250 | 245 | 249 | 261 | 271 | 270 | 269 | 265 | 270 | 274 |
| Nilamma Choudhari    | 66 | F | 109072 | Yes | 10 years | Yes | 8.5 | 194 | 344 | 207 | 12 | 10.3 | Yes | 1 year  | Diabetic Nephropathy               | Severe NPDR                      | Severe NPDR                      | 176 | 177 | 169 | 173 | 167 | 180 | 176 | 173 | 179 | 180 |

## Annexure VI

## Plagiarism report


Page 2 of 61 - Integrity Overview

Submission ID trrcoid::3618/93237307

## 8% Overall Similarity

The combined total of all matches, including overlapping sources, for each database.

### Filtered from the Report

- Bibliography
- Quoted Text
- Small Matches (less than 10 words)

### Exclusions

- 2 Excluded Websites

#### Match Groups


**54 Not Cited or Quoted 8%**  
Matches with neither in-text citation nor quotation marks


**1 Missing Quotations 0%**  
Matches that are still very similar to source material


**0 Missing Citation 0%**  
Matches that have quotation marks, but no in-text citation


**0 Cited and Quoted 0%**  
Matches with in-text citation present, but no quotation marks

#### Top Sources

7%

Internet sources

5%

Publications

0%

Submitted works (Student Papers)

### Integrity Flags

#### 1 Integrity Flag for Review


**Hidden Text**  
265 suspect characters on 4 pages  
Text is altered to blend into the white background of the document.

Our system's algorithms look deeply at a document for any inconsistencies that would set it apart from a normal submission. If we notice something strange, we flag it for you to review.

A flag is not necessarily an indicator of a problem. However, we'd recommend you focus your attention there for further review.


Page 2 of 61 - Integrity Overview

Submission ID trrcoid::3618/93237307

## REFERENCES

1. Global Burden of Disease Collaborative Network. Global, regional, and national burden of chronic kidney disease 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020;395(10225):709–33.
2. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and mortality for 250 causes of death: reference and alternative scenarios for 2016–40. *Lancet*. 2018;392(10159):2052–90.
3. Vaidya SR, Aeddula NR. Chronic renal failure. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; 2022.
4. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. *Lancet*. 2013;382(9888):260–72.
5. Singh AK, Farag YM, Mittal BV, et al. Epidemiology and risk factors of chronic kidney disease in India – SEEK study. *BMC Nephrol*. 2013;14:114.
6. Kovesdy CP, Kalantar-Zadeh K. Diabetes mellitus and kidney disease: an update. *Nat Rev Nephrol*. 2022;18(11):733–47.
7. Stanifer JW, Muir A, Jafar TH, Patel UD. CKD in low- and middle-income countries. *Nephrol Dial Transplant*. 2016;31(6):868–74.
8. Modi GK, Jha V. The incidence of end-stage renal disease in India. *Kidney Int*. 2006;70(12):2131–3.
9. Wong TY, Mitchell P. The eye in hypertension. *Lancet*. 2007;369(9559):425–35.
10. Chew M, Sabanayagam C, Tay WT, et al. Retinopathy signs and CKD in persons without diabetes: SEED study. *PLoS One*. 2016;11(3):e0149448.

11. Da Silva MO, Chaves AE, Gobbato GC, et al. Early choroidal changes in diabetes and CKD. *BMJ Open Diabetes Res Care*. 2022;10:e002938.
12. Chow JY, She PF, Pee XK, et al. pRNFL and macular thickness in non-diabetic CKD. *PLoS One*. 2022;17(4):e0266607.
13. Suryakanth S, Ravi Shankar HN, Heralgi MM, et al. Hemodialysis effect on macular thickness in ESRD. *Taiwan J Ophthalmol*. 2021;11(4):367–71.
14. Sivakumar V, Shobhana M, Mahesh V, et al. Diabetic nephropathy in urban/rural South India. *Int J Diabetes Dev Ctries*. 2021;41(1):74–80.
15. Johnson DW, Jones GR, Mathew TH, et al. eGFR reporting in CKD. *Med J Aust*. 2012;197(4):224–5.
16. Tummalapalli SL, Johansen KL, Hailpern SM, et al. Disparities in nephrology referrals in India. *Clin J Am Soc Nephrol*. 2021;16(4):631–9.
17. Rao BS, Prasad N, Sharma RK, et al. CKD in rural Karnataka: epidemiology. *Indian J Nephrol*. 2015;25(6):363–70.
18. Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging SD-OCT. *Am J Ophthalmol*. 2008;146(4):496–500.
19. Mookiah MRK, Acharya UR, Koh JEW, et al. Diagnostic assessment of diabetic macular edema. *Comput Biol Med*. 2020;120:103717.
20. Chua J, Lim CXL, Wong TY, et al. Diabetic retinopathy and systemic vascular complications. *Prog Retin Eye Res*. 2021;83:100902.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16(1):31–41.

22. Lim LS, Cheung CY, Wang JJ, et al. Retinal vascular imaging and CKD. *Curr Opin Nephrol Hypertens*. 2011;20(6):621–7.
23. Kuo JZ, Wong TY, Rotter JI. Genetics of microvascular complications in diabetes. *Curr Diab Rep*. 2015;15(7):36.
24. Pugliese G, Penno G, Natali A, et al. Diabetic nephropathy: new clinical and therapeutic perspectives. *J Nephrol*. 2020;33(1):9–35.
25. Kim M, Kim G, Lee JY. Association between renal function and choroidal thickness. *Br J Ophthalmol*. 2020;104(12):1708–13.
26. Vujosevic S, Micera A, Bini S, et al. Early microvascular retinal changes in diabetes. *Eye*. 2021;35(1):115–21.
27. Liu F, Wang X, Zhang Y, et al. Retinal changes in non-diabetic CKD patients on dialysis. *Ren Fail*. 2021;43(1):258–64.
28. Spaide RF, Fujimoto JG, Waheed NK. Optical coherence tomography angiography. *Prog Retin Eye Res*. 2018;64:1–55.
29. Heralgi MM, Suryakanth S, Mahesha S, et al. Retinal and OCT changes in ESRD. *Indian J Ophthalmol*. 2021;69(5):1232–8.
30. Cheung CY, Ikram MK, Sabanayagam C, Wong TY. Retinal microvasculature as biomarker in renal diseases. *Curr Opin Nephrol Hypertens*. 2012;21(3):245–51.
31. Chow S, Choi DH, Youn S, et al. Peripapillary RNFL thinning and renal function. *J Clin Med*. 2022;11(2):376.
32. Sharma S, Saurabh K, Krishnan T, et al. OCT biomarkers in retinal and systemic diseases. *Surv Ophthalmol*. 2021;66(5):875–95.
33. Yu H, Chen Y, Lin W, et al. Retinal nerve fiber layer in polycystic kidney disease. *Kidney Blood Press Res*. 2020;45(2):254–61.
34. Zhang Y, Liu X, Jin Y, et al. Microvascular abnormalities and systemic vascular indicators in CKD. *Front Med (Lausanne)*. 2021;8:654772.
35. Zhi Z, Wang RK. Optical microangiography of retina and kidney. *J Biophotonics*. 2018;11(10):e201700346.

